



Ed and Ethel Moore Alzheimer's Disease Research Program

Funding Opportunity Announcement

FY 2024-2025

TABLE OF CONTENTS

Ed and Ethel Moore Alzheimer’s Disease Research Program Funding Opportunity: FY 2024-2025

Contents

I.	OVERVIEW	4
1.	<i>Introduction</i>	4
2.	<i>Priority Areas</i>	4
	Priority Area 1:	4
	Priority Area 2:	9
	Priority Area 3:	11
	Priority Area 4:	13
	Priority Area 5:	14
3.	<i>Grant Categories</i>	15
4.	<i>Highlights</i>	17
5.	<i>Schedule of Important Dates</i>	19
II.	ELIGIBILITY AND APPLICATION REQUIREMENTS	22
1.	<i>Alzheimer’s Disease-Relatedness</i>	22
2.	<i>Eligibility Requirements</i>	22
3.	<i>Required Grant Application Components</i>	25
4.	<i>Allowed and Disallowed Costs</i>	27
5.	<i>Inquiries and Contacts</i>	29
6.	<i>Requirements for Protecting Intellectual Property</i>	29
7.	<i>Definitions</i>	29
III.	INSTRUCTIONS FOR APPLICATION PREPARATION AND SUBMISSION	33
IV.	AFTER APPLICATION SUBMISSION	35
1.	<i>Changes to a Submitted Application</i>	35
2.	<i>Evaluation of Applications</i>	35
3.	<i>Notification of Funding Decision</i>	36
4.	<i>Requests for Re-Consideration</i>	36
5.	<i>Grantee Requirements</i>	37
V.	APPENDIX	38
1.	<i>Reportable Financial Interests</i>	38
2.	<i>Budget Guidance</i>	39
3.	<i>Terms and Conditions Template</i>	446
	Attachment II	64
VI.	ATTACHMENT VI	65
	EXHIBIT 1.....	71
	EXHIBIT 2.....	72
	EXHIBIT 3.....	73
	EXHIBIT 4.....	74

All awards in response to this Funding Opportunity are subject to the availability of funds and spending authority provided by the Florida Legislature. By submitting a grant application pursuant to this Funding Opportunity, all applicants acknowledge and consent to this condition.

Direct all questions about the online application process and related issues to:

Florida Department of Health
Public Health Research Unit
Division of Community Health Promotion
4052 Bald Cypress Way Bin A24
Tallahassee, Florida 32399-1725
Office: 850-245-4585

Email: Research@flhealth.gov

Website Links: [Peer Net Grant Application Submission Portal](#)

[Ed and Ethel Moore Alzheimer's Disease Research Program Website](#)

I. OVERVIEW

1. Introduction

The Ed and Ethel Moore Alzheimer’s Disease Research Program (hereafter referred to as the “Program”), is established in section 381.82, Florida Statutes. The purpose of the Program is to fund research leading to prevention of, or a cure for, Alzheimer’s disease by pursuing the following goals:

1. Improve the health of Floridians by researching better prevention and diagnoses of, and treatments and cures for Alzheimer’s disease.
2. Expand the foundation of knowledge relating to the prevention, diagnosis, treatment, and cure of Alzheimer’s disease.
3. Stimulate economic activity in Florida in areas related to Alzheimer’s disease research.

The State Health Improvement Plan (SHIP) established Priority Area 1 for Alzheimer’s Disease in 2022. The goals of SHIP Priority Area 1 are:

1. Strengthen the capacity to address Alzheimer’s Disease and Related Dementias (ADRD) in Florida.
2. Assure a Competent ADRD Workforce Through Education and Training
3. Enhance Support for Those Living with ADRD and Their Caregivers in Florida

Funding is anticipated for research grants awarded in 2024-2025 based on the availability of funding. This document will provide the detailed information needed for completing a Letter of Intent and the grant application.

2. Priority Areas

The purpose of this Funding Opportunity Announcement (FOA) is to stimulate research relating to the prevention, diagnosis, treatment, care management, and cure of Alzheimer’s disease (AD) that is of the highest priority and potential benefit to the people of Florida. The FOA is designed to support grants, ranging from pilot research to more mature projects, that are attempting to advance a therapeutic approach or concept. Consortium grants are encouraged for maximum return on results. Research investigators from diverse and underserved populations are encouraged to apply. Special attention should be directed to the needs of racial, ethnic, and other underserved populations who may be at risk for or dealing with Alzheimer’s disease. Priority will be given to applications that involve populations that have been historically underrepresented in research. This program anticipates this will be achieved by supporting research in the following five priorities:

Priority Area 1:

Objectives: This FOA aims to stimulate the discovery and validation of a broad spectrum of potential therapeutic strategies for dealing with the behavioral and social needs of persons with AD and their caregivers. The major overall goal of this FOA is to foster novel ideas relating to

underdeveloped/underfunded areas of research that will then lead to transformative advances and major funding from the National Institutes of Health (NIH), not-for-profit foundations, other appropriate resources, or in some cases licensing of a technology by a for-profit entity. The FOA is designed to support grants; ranging from pilot research to more mature projects, that are attempting to advance a therapeutic approach or concept. Consortium grants are encouraged for maximum return on results. Special attention should be directed to the needs of racial, ethnic, and underserved populations. Priority will be given to applications that involve populations that have been historically underrepresented in research.

Background: The current national portfolio for AD research is focused primarily on the biomedical aspects of AD. The National Alzheimer's Project Act specifically includes two goals related to behavioral and social aspects of care: Goal 2: Enhance Care Quality and Efficiency; and Goal 3: Expand Support for People with AD and Their Families. Further, there is a desperate need for research into changes in care processes that will lead to improvement in the lives of people with Alzheimer's Disease, and their caregivers. This FOA Priority is designed to encourage novel studies that can lead to transformative advances in care.

Focus Areas: (The applicant must state clearly, which of these areas the proposal addresses.)

Focus Area 1.1 Behavioral. "Behavioral expressions," formally called psychiatric manifestations of dementia, are common and difficult problems. Often, these lead to caregiver exhaustion and the transfer of care to institutional care facilities. The antipsychotic, anti-seizure, anti-anxiety, and antidepressant medications may not be effective treatment options or may have serious side effects, including death. Centers for Medicare and Medicaid Services, partnered with state and federal agencies, special memory care facilities, community agencies and programs (in-home or in-facility), respite care services, and volunteer programs, improve the quality of care and life of diagnosed persons and their caregivers. While many such resources were initially developed to reduce the use of antipsychotic medications, the national partnership's main goal is to encourage the use of non-pharmacological approaches and person-centered AD care practices to optimize the functioning of persons with AD and related dementias, reduce caregiver stress, and provide person-centered care practices. Although many facilities have developed special units for managing persons with these problems, there has been limited research into their effectiveness. Consortium partnerships of such programs and services with research institutions to examine effectiveness is strongly encouraged for maximum return on results. Special attention should be directed to the needs of racial, ethnic, and underserved populations. High priority will be given to research on:

- Evaluation of antecedents and triggers of "behavioral expressions"
- Testing of non-pharmacological interventions (e.g., physical exercise, group activities, music, diet, bright light therapy, play therapy, replacement therapy, pet therapy, massage, Snoezellen rooms) for "behavioral expressions."
- Comparative evaluations of different types of facilities, such as memory care units or geropsych units, for clinical outcomes and cost-effectiveness.
- Proof of concept proposal demonstrating a community model for ways to increase access to current and emerging methods of evaluation and treatment of individuals with cognitive impairment and acute psychiatric/behavioral disturbances.
- Demonstration project providing alternatives to utilizing the Baker Act in the setting of acute agitation/behavioral disturbances.
- Demonstration project providing alternative and novel pharmacological approaches to

treat agitation/behavioral disorders.

- Development of more specific and sensitive screening tools to diagnose people with psychiatric disorders who present with AD.

Focus Area 1.2 Social. The social environment for people with AD plays an important role in disease management, progression, and health care costs. The scope of this focus area includes interventions to reduce caregiver burden and to improve the quality of care across various settings including individuals, families, and communities through resource improvement or education.

1.2.1 Resources: Sometimes individuals are diagnosed with AD or other types of dementia but do not receive referral information to community-based resources. Some communities, particularly rural communities, have few services available such as support groups, respite care, or caregiver education, safety training or driver fitness (including driver rehabilitation and safe behaviors for drivers, passengers, other motor vehicles, and pedestrians). Consortium work is encouraged for maximum return on results. High priority will be given to research on:

- Technological interventions for assisting people with Alzheimer's or caregivers (e.g., application development, use of robotics, sensors, locator devices, reminders, virtual reality related technology).
- Technological assistance for improving quality of care in adult day care or other residential settings in rural places where there may be few or no existing resources.
- Interventions to help caregivers navigate the interface of formal and informal care and acquire seamless care coordination.
- Barriers to access and utilization of long-term care resources including home and community-based services such as adult day care services, foster/group homes, nursing homes, memory care programs, assisted living facilities, hospice care services.
- Memory rehabilitation programs.
- Research on differences in quality of care received amongst diverse sociodemographic settings secondary to lack of opportunities.
- Analysis of alternative environmental design to promote greater independence and reduce adverse behaviors (e.g., dementia-friendly housing, communities and gardens, as well as person-centered care such as Eden Alternative).
- Transportation barriers, driver fitness and rehabilitation, and driving related issues seen with AD.
- Developing useful resources to help caregivers with planning ahead such as financial and legal planning, emergency back-up plans, etc.
- Developing safety resources, interventions, support groups and other community resources to address abuse, neglect, and exploitation of people with AD or their caregivers.

1.2.2 Education: Amongst professionals who provide services to persons with AD, there is a wide variation in knowledge, skills, and level of confidence about their interactions with persons with cognitive impairment who may or may not have yet been diagnosed with AD. Similarly, there is a wide spectrum of these features amongst caregivers of diagnosed persons or caregivers of individuals with cognitive impairment who have not yet received a diagnosis. In addition, there are cultural differences in how cognitive impairment and/or a diagnosis of AD is addressed or received by the diagnosed person and/or their caregiver. Many people with AD and other dementias have acknowledged the "stigma" of the diagnosis. The lack of attention to these types of factors contributes to adverse health outcomes and high costs of care. Consortium work is encouraged for maximum return on results. High priority will be given to

research on:

- Establishing and conducting educational programs that will work to equip the relevant workforce and/or their trainees, for example, healthcare professionals (physicians, dentists, nurse practitioners, physician assistants, nurses, nursing aides, pharmacists, social workers, physical therapists, occupational therapists, speech therapists, music therapists, healthcare profession faculty, etc.) and health profession trainees (students, residents, fellows), first responders (such as emergency medical technicians, paramedics, firefighters, and police officers), and staff and/or volunteers of community-based organizations that provide services to seniors with knowledge and skills to help optimize their engagement with and to improve health outcomes for persons with AD and/or their caregivers.
- Optimal methods for communicating the diagnosis to persons with AD and/or their caregivers.
- Applied research into different types of AD caregiver training (e.g., The Best Friends Approach and Dementia Care Mapping).
- Methods of assessing surrogate decisions for continued care and their fidelity with the wishes and preferences of the diagnosed person.
- Education and training about responding to acute behavioral emergencies for caregivers of diagnosed persons, and for first responders and similar community health and service providers who address acute behavioral emergencies in persons with AD.
- Education and training for caregivers related to planning ahead such as financial and legal planning, emergency back-up plans such as for health-related emergencies, public health emergencies, weather emergencies or for when the caregiver is temporarily or no longer able to provide care.

1.2.3 Novel Challenges: Many persons living with AD and their families face a wide range of social, functional, economic, technological, and ethical challenges. These same challenges may be particularly important for individuals who have not yet received a diagnosis. There is a lack of information about how these various challenges are met by persons living with AD and their families or how social, functional, economic, technological, and ethical challenges impact their quality of life and ability to age in place. Consortium work is encouraged for maximum return on results. High priority will be given to research on:

- Ethical issues in seeking, obtaining, and/or living with a diagnosis of AD.
- Financial planning and paying for ongoing medical/health care or home care of persons living with AD.
- Abuse, neglect, or exploitation of older adults with AD and/or their caregivers.
- The impact of social isolation due to medical/social situations.
- Challenges with technology and aging in place.

Focus Area 1.3 Palliative and End-of-Life Care. AD and related dementias were officially listed as the sixth leading cause of death (COD) in the United States in 2019, and recent estimates by the National Institute on Aging (NIA) suggest it is the seventh leading COD in those over age 65. Because of an improvement in early diagnosis, people live many years with AD before they die.

1.3.1 Advance Care Planning: While the other common causes of death are associated with preservation of cognition, often until the very end of life, persons with AD and related dementias typically lose the ability to direct their own care long before the time of death. Surrogate

decision-making is the norm. Some studies have shown that family caregivers have a low to moderate agreement with diagnosed persons on preferences for end-of-life treatment. This highlights how planning for care at the end of life is affected by uncertainty, even when the caregiver and person with AD may perceive the caregiving/care receiving relationship to be sound and satisfactory. Little is known about the status of personal advance care planning for caregivers of diagnosed persons, and its relationship with advance care planning for persons with AD. Advance care planning is known to improve end-of-life care and patient and family satisfaction and it reduces stress, anxiety, and depression in surviving family members and caregivers. Consortium work is encouraged for maximum return on results. High priority will be given to research on:

- Promotion and best practices for conducting Advance Care Planning (ACP) discussions in persons with AD and/or caregivers of persons with AD (e.g., Engage with Grace – The One Slide Project, The Conversation Project, Caring Conversations, ACP Decisions videos, Go Wish Cards, Five Wishes, Aging with Dignity, Healthy Aging Healthy Brain, and Project Ready).
- The use of online advance directives in persons with early AD and/or caregivers of persons with AD (e.g., PrepareForYourCare.org, MyDirectives.com, the Letter Project form, Five Wishes, Aging with Dignity).
- Effective approaches to promote ACP (discussions and completion) as part of primary care services for persons with early AD and/or their caregivers.

1.3.2 Multimorbidity: There is high prevalence of comorbid conditions in people with AD. Neuropsychiatric symptoms (NPS) are known to increase with cumulative comorbidity burden. The presence of AD may confound clinical care for other conditions and challenge the ability to manage their chronic conditions. Little is known or has been explored about systems and processes currently in place for the care of people with AD who have comorbid medical conditions, and about the experiences of people with AD who have comorbid medical conditions and their family caregivers. There is a need for more research looking at the ways in which having AD influences clinical care for other conditions and how systems, processes of care, and different services adapt to the needs of people with AD and multiple comorbid conditions. In addition, coordination and planning for the management of multiple comorbid conditions in a person with early to moderate to advanced signs or diagnosis of AD, in keeping with the person's personal goals of care while balancing potential benefits with recognized harms, can be a challenge. Consortium work is encouraged for maximum return on results. High priority will be given to research on:

- Analysis of methods for decision-making on discontinuing treatments of co-morbid conditions in advanced AD, for example, based upon goals of care, life expectancy, time to benefit, treatment targets, and balance between potential benefits and potential or recognized harms of treatments.
- Application of recommendations from the Choosing Wisely campaign that promotes conversations between clinicians and diagnosed persons to choose care that is supported by evidence, not duplicative of other tests or procedures already received, free from harm, and truly necessary (e.g., American Geriatrics Society Choosing Wisely Campaign: Ten Things Clinicians and Patients Should Question).

1.3.3 Palliative Care: ADs are life limiting conditions with mounting prevalence and multifaceted needs. Palliative care needs of persons with AD are often not recognized or inadequately addressed. Symptoms, such as pain, are under treated while these persons are over-subjected

to burdensome interventions with often additional accumulation of symptoms or distress, or functional compromise related to the burdensome interventions. Palliative care may be described as person and family centered care that optimizes quality of life by anticipating, preventing, and treating suffering. Palliative care, throughout the continuum of illness, involves addressing physical, intellectual, emotional, social, and spiritual needs, as well as, facilitating the autonomy, access to information, and choices of the person with the diagnosis.

The delivery of palliative care can be differentiated from the delivery of hospice care. Palliative care is delivered as inter-professional care that aims to relieve physical and emotional suffering, improve quality of life, optimize function, and assist with decision-making for people with advanced illness and their families/care partners. It is offered simultaneously with all other disease-modifying medical treatments, either by the primary medical team or in conjunction with a palliative care consultant. Hospice services in the United States are specialized palliative care limited to people who meet two criteria: a) their life expectancy is <6 months if their disease takes its natural course, and b) they (or their proxies) have elected to focus on comfort measures and forgo curative treatment. Consortium work is encouraged for maximum return on results. High priority will be given to research on:

- Examination of reasons or attitudes for avoiding or delaying palliative care planning.
- Best practices for palliating symptoms in persons with early to moderate to advanced AD.
- Education of caregivers or healthcare surrogates about optimal timing of transition in care for a person with advanced AD to palliative care or hospice care.
- Inter-professional palliative care education or hospice training for care providers of diagnosed persons.
- Effective approaches for transition in care for a person with advanced AD to palliative care or hospice care, including optimal processes for communication (e.g., based on the applicable components of the 7 Cs of the Gold Standard Framework: communication, coordination, control of symptoms, continuity, continued learning, caregiver support, and care of the dying).

1.4 Novel Health Solutions: Translational Science aims to turn research observations into improved health and quality of life. The major overall goal is to foster novel ideas relating to additional treatment options for impacted individuals more quickly that will help secure funding from national and other resources. Interventions should aim to improve the health of individuals and the public — from diagnostics and therapeutics to medical procedures and behavioral changes. All applications that evaluate non-pharmacological interventions to improve the care of people living with AD/ABRD and their care partners will be considered. Consortium grants are encouraged for maximum return on results.

Priority Area 2:

Objectives: This FOA aims to stimulate a) the discovery and validation of a broad spectrum of potential therapeutic targets or novel therapeutic strategies, b) provide novel insights into the pathophysiology of AD, and c) identify novel biomarkers. The major overall goal of this FOA is to foster novel ideas relating to underdeveloped/underfunded areas of research that will then lead to transformative advances and major funding from the NIH, not-for-profit foundations, other appropriate resources, or in some cases licensing of a technology by a for-profit entity. The FOA is designed to support grants ranging from pilot research to more mature projects that are attempting to advance a therapeutic concept or approach. Consortium work is encouraged for

maximum return on results. Priority will be given to applications that involve populations that have been historically underrepresented in research.

Background: The current national portfolio for AD research is rather conservative and many questions about the pathophysiology of AD remain poorly explored. Further, there is a desperate need to develop novel therapeutic approaches and strategies. This FOA is designed to encourage novel studies that can lead to transformative advances.

Focus Areas: (The applicant must state clearly which of these areas the proposal addresses.)

Focus Area 2.1 Novel therapeutic targets and strategies. The development of novel therapeutics aimed at slowing and eventually preventing the progression of AD remains a critically important public health goal. Further, there is a need for better therapies that can improve symptoms or alter the disease course even at later stages of disease. High priority will be given to novel therapeutic approaches. These may include novel approaches to target known factors (e.g., amyloid, tau), identification of new targets, evaluation of combination therapies, non-pharmacologic interventions, or even non-traditional interventions (e.g., nutraceutical interventions and chair yoga). Studies may range from pure target discovery to high throughput screening campaigns to preclinical proof of concept studies to pilot or small clinical trials. For more advanced technologies, initial, small, Primary Investigator (PI)-initiated Investigational New Drug (IND) enabling studies may be proposed.

Focus Area 2.2 Mechanisms of neurodegeneration. There is considerable evidence that AD is a complex proteinopathy in which accumulation of Abeta and tau proteins and other proteins play a pivotal role. However, we have a relatively poor understanding of how these proteinopathies cause neurodegeneration. High priority will be given to applications that provide novel insights into cellular pathways and other mechanisms of neurodegeneration. These proposals, for example, may address questions such as: 1) How does Abeta trigger tau pathology? 2) What is a dystrophic neurite? 3) Why are some populations of neurons vulnerable? 4) What is the role of innate immune activation? 5) What early changes in neurochemistry such as protein misfolding in neurons that predispose to developing AD and implications for therapies? Studies should expand beyond current paradigms (such as primary culture toxicity of Abeta) to address these questions.

Focus Area 2.3 Understanding co-morbidities and other factors that contribute to progression of AD. There is increasing evidence that co-morbidities may dramatically alter the course of AD. Further, other events such as infection, surgery, acute or repeated head traumas, and hospitalization, appear to accelerate cognitive decline. Conversely, there are factors that may slow progression (e.g., physical exercise). High priority will be given to applications that can provide fundamental insights into how co-morbidities and other potentially modifiable risk-factors contribute to cognitive decline and dysfunction.

Focus Area 2.4 Novel biomarkers. Novel biomarker approaches, especially those that may identify biomarkers of AD risk or AD progression (as opposed to state dependent biomarkers) will be given high priority for funding.

Focus Area 2.5 Biological basis of novel genetic risk factors or genetic therapies in Alzheimer's Disease. Applications that explore the biological mechanism of genetic risk factors, identified by Genome Wide Association Studies (GWAS), genomic sequencing, or other genomic approaches associated with preventing or treating AD and related dementias will be

given high priority. These studies should focus on novel loci (e.g., not amyloid precursor protein (APP), apolipoprotein E (APOE), Presenilin-1 (PSEN1), or Presenilin-2 (PSEN2)) or other genetic studies such as altering DNA by installing one or more protective genes to prevent AD, or to stop or reverse the decline of AD. Studies may range from attempts to identify the functional variants within a genetic locus to evaluating the biological impact of genes within established genetic loci.

Priority Area 3:

Objectives: This FOA aims to stimulate a consortium of clinical centers to conduct high quality clinical research studies of greater breadth than described in Priority 2, Focus Area 2.1. The consortium should involve partnerships to be developed among investigators across Florida, in such fields as neuromedicine (i.e., neurology, psychiatry, neuroimaging, neuropsychology, etc.), neuroengineering, neurotechnology, geriatrics, gerontology, pharmacology, nutrition, physical therapy, occupational therapy, speech pathology, nursing, and clinical social work. The consortium should develop common clinical protocols using electronic databases to address one or more areas of research interest and to support the exploration of the focus areas listed within Priority Area 3. Grants may range from pilot research to more mature projects that are attempting to advance a therapeutic approach or concept. Priority will be given to applications that involve populations that have been historically underrepresented in research.

Background: There are several academic medical centers in Florida that have developed their own infrastructure for conducting high quality clinical and diagnostic projects and have received federal, state and private foundation grants to support these activities. However, many clinical organizations and Memory Disorder Clinics (MDC) in Florida have an interest in conducting studies in the fields of AD, Mild Cognitive Impairment (MCI) that may precede Alzheimer's disease, and normal cognitive aging that raise questions of an early stage of Alzheimer's disease and related dementias but lack such an infrastructure. To promote the development of the infrastructure to support such clinical research studies, applications may be submitted by any university or established research institute in Florida, with existing infrastructure and clinical and behavioral research protocols to collaborate with MDCs and other clinical organizations which are without such existing infrastructure.

In addition, there is a need to highlight the importance of reaching out to rural research programs, emerging research programs, or colleges/universities less established in Alzheimer's disease research. Mentorship involving experienced, well established research institutions could strengthen the less established group's science and guidance for future funding, as well as expand the breadth and range of Alzheimer's disease research. In an effort to promote the development of the infrastructure to support such conceptual, basic, clinical and behavioral research studies that involve mentoring those institutions who have not received funding from the Ed and Ethel Moore Alzheimer's Disease Research Program, special consideration and high priority will be given to encourage a consortium with the lead organization including in its collaboration at least one less established Alzheimer's research organization in a consortium of at least three collaborating institutions.

Applications may be submitted by any university or established research institute in Florida, with existing infrastructure and clinical and behavioral research protocols to collaborate with MDCs and other clinical or academic organizations with minimal or no such existing infrastructure. This type of consortium will promote the development of more robust academic and clinical center programs to conduct high quality clinical research studies. An application submitted by any

existing or established university or research institute, that collaborates with a less established research organization or clinical organization or community-based or hospital-based, free-standing MDC must show a clear and high quality research relationship, collaboration, infrastructure, and a mentorship protocol with clear expectations, goals, and collaborative team approach in the application that focus on early to late changes and the challenges of AD. This will promote the development of a consortium of clinical centers to conduct high quality clinical research studies.

Focus Areas: (The applicant must state clearly which of these areas the proposal addresses.)

Focus Area 3.1 Risk factors for cognitive decline that may precede signs of AD. These risk factors may include exposure to stress, anesthesia, surgery, acute and repeated head traumas, chronic health conditions such as cardiovascular conditions, and lifestyle factors. Priority will be given to applications that involve populations that have been historically underrepresented in research.

Focus Area 3.2 Underlying pathophysiology. Providing a better understanding of the pathophysiology underlying those at high risk for AD (e.g., the interaction of cytokines and inflammation to cerebrovascular disease and neurodegeneration detected on imaging such as structural and functional magnetic resonance imaging (MRI)).

Focus Area 3.3 Treatment protocols. The development of novel treatment protocols.
Focus Area 3.4 Evaluating the influence of changes in brain structure. Evaluating the relationships of psychiatric and cognitive features of disease to regional changes in brain structure and function.

Focus Area 3.5 Expert diagnosis system. Developing a valid expert diagnosis system to improve and validate diagnoses of AD by health care professionals across Florida. The expert system could have both electronic and human expert components.

Focus Area 3.6 Comprehensive protocol for care management with links to support services over the course of decline. Providing a careful diagnosis is important but providing the person with the diagnosis and the caregiver(s) with educational information and referrals to community resources is equally important. Along the course of decline, educational handouts and internet links may provide practical tips and guidelines for the family to plan for changes over the course of the disease, referrals for health and social services and accessible resources in the community such as senior center activities, occasional or daily (health) care centers, and support groups. Studies of protocols for diverse populations such as racially, ethnically, or culturally different or rural Floridians or programs such as at community centers or staffed with volunteers at civic or religious organizations may provide models of best and cost-effective practices for long-term quality of life during ongoing decline.

Focus Area 3.7 Normative neuropsychological database. Developing a Normative Neuropsychological Database for the purpose of developing standards for neuropsychological diagnosis, accounting for age, primary language, race, ethnicity, educational achievement, occupation, cognitive reserve, socioeconomic status, and other lifestyle factors. The ethnic diversity in Florida provides both a challenge for neuropsychological diagnosis as well as an opportunity to provide the nation with invaluable normative data. Priority will be given to applications that involve populations that have been historically underrepresented in research.

Priority Area 4:

Objectives: This FOA includes priorities in epidemiology to address the needs of Florida's diverse population. This FOA will fund epidemiologic studies that improve our understanding of genetic, epigenetic, and acquired neurodegenerative, cardiac, and vascular disorders that result in cognitive impairment and AD and how these conditions affect Floridians. Priority will be given to applications that involve populations that have been historically underrepresented in research.

Background: The population of older adults in Florida continues to grow through the aging of its population and the influx of older adults from other parts of the U.S. and abroad. Minorities, especially Hispanic and African American populations, are growing demographics and the risk factors, prevalence and incidence in Florida, course, and outcomes of neurocognitive disorders that are specific to these and other people in Florida's diverse population (inclusive of racial and ethnic diverse people, people with low income, people living in rural areas, people with limited English language skills, people with intellectual and/or developmental disabilities and people with acquired disabilities) are not well understood. For example, vascular disease is both preventable and treatable, but studies are needed that focus on identifying specific populations at risk for developing AD and clarifying the risk factors to target. Access to care is limited for many Floridians, including those in both urban and rural areas and each of these populations has special needs.

Focus Areas/Themes: (The applicant must state clearly which of the following areas the proposal addresses.)

Focus Area 4.1 Disproportionately Impacted Floridians. Studies that include fluid and pathologic biomarkers of the diseases that impact different populations. The FOA encourages the inclusion of diverse populations, people with low income, people living in rural areas, people with limited language skills, people with disabilities, and the underserved. An overarching goal of studies in this focus area is to identify genetic, environmental, and other factors that influence disease incidence, presentation, and course. Studies that incorporate life course methods to assess the contributions of particular risk factors are encouraged.

Focus Area 4.2 Cardiovascular contributions to neurocognitive disorders. Increasing evidence suggests that cardiovascular dysfunction, endothelial decline, and amyloid angiopathy play critical roles in the development and progression of AD and cardiovascular dementia and little is known about the interaction of cardiovascular factors in other neurodegenerative dementias. Epidemiological studies that examine these interrelationships and include biomarkers such as vascular brain imaging, fluid biomarkers of inflammation and vascular risk, cardiac health risk factors, and markers of the underlying neurodegenerative process will be given high priority. Studies that incorporate non-invasive markers of cardiovascular injury are encouraged.

Focus Area 4.3 Early detection. Pathological studies suggest that amyloid deposition and proteinopathies occur decades before cognitive symptoms begin in AD and the role of environmental and potentially modifiable factors at the earliest stages is not well understood. Epidemiologic studies using novel methods to detect the earliest cognitive, functional, and endophenotypic changes (e.g., brain imaging, fluid biomarkers) of AD and other neurocognitive disorders are encouraged. Studies that make use of community engagement methods to include at-risk populations not normally involved in research will be prioritized.

Priority Area 5:

Objectives: This FOA aims to provide clinical, patient-oriented research fellowship training that stimulates a) novel insights into the brain-mediated function and dysfunction related to AD, b) discovery and validation of novel diagnostic strategies related to symptomatology of AD, and c) discovery and validation of novel treatment and care management strategies of AD.

Organizations must have a certified fellowship-training program or an established training program for health professionals to be considered eligible. Submission of a competitive NIH Award application or comparable grant application is a required grant deliverable in the final grant year.

Background: The current national opportunities for clinical fellowship training of physicians and PhDs and comparable terminal degrees in patient-centered AD research is rather limited leading to a paucity of experts and research mentors available to address the many challenges for accurate diagnosis and care management over the long course of decline. A major public health goal is to promote healthy brain function and prevent the onset or progression of AD. There is a desperate need to develop novel therapeutic approaches and strategies that can be adapted to individual variation in the presentation of symptoms as well as the training of medical and other health-related experts in effective diverse protocols for accurate diagnosis, treatment, and care strategies. The gap of expertise in addressing the impacts of AD also has led to the inadequacy of community resources to help patients maintain optimal quality of care in a community-based setting. Of special need are underserved populations dealing with AD. This FOA is designed to support physician or PhD (or comparable terminal degree) in postdoctoral fellowship training that fosters and advances clinical research training (e.g., clinical service, evaluation, neurochemistry, neurosciences, neuromedicine, neurotherapeutics, neuropathology, neuropharmacology) to develop expert health provider research skills focused on people with AD and to encourage attention to the challenges of diverse and underserved people dealing with AD.

Focus Areas: *(The applicant must state clearly which of the following areas the proposal addresses and clearly outline how their work within the focus area relates to Priority Areas 1-4.)*

Focus Area 5.1 Novel training to address inadequate number of highly trained patient-centered researchers. The postdoctoral research training occurs in an underdeveloped or underfunded specialty area of patient-centered research on AD. Research fellowship training will lead to transformative advances in patient-centered evaluation, diagnosis (including clinical diagnosis and/or post-mortem neuropathological diagnosis), treatment, assistive technology, and care management skills and research. An outcome of the training is preparation of an application for major funding, for example, from the NIH, other federal agency, not-for-profit foundation, or other appropriate funding resources.

The research fellowship training involves learning how to: review the literature on basic or brain-mediated areas of function and dysfunction; develop hypotheses and the methodology to test these hypotheses on diagnosed persons, family members, care partners, and control subjects based on their willingness to volunteer for the research; develop a protocol that receives Institutional Review Board (IRB) approval from the research institution; recruit volunteer participants as subjects (with double informed consent, as appropriate, provided by people with AD); collect data; analyze results; present the data and write articles for presentations at professional meetings; write up results for refereed professional journals; and translate results

into information for lectures, appropriate treatments, caregiving strategies, and for simple practical informational handouts or suggestions for people diagnosed with AD, family and professional caregivers/care partners, health and social service providers, and the general public.

Focus Area 5.2 Understanding brain-mediated function and dysfunction and therapeutic strategies. The postdoctoral research training fellowship covers scientific research and must be related to parameters of AD. The parameters may include brain-mediated function, assessment tools, diagnostic techniques, therapeutic interventions, care management strategies, assistive technology, and support services for people suffering from AD. Basic clinical or translational research may involve basic brain-mediated behavior studies based in the clinical setting and may deal with deficits in memory, attention, language, visual-spatial functions, movement problems, and related cognitive dysfunctions that are experienced by people with symptoms of decline related to AD.

Focus Area 5.3 Novel diagnostic procedures, tools, and strategies. The development of novel diagnostic evaluation procedures, may involve assessment tools, treatments, and therapeutic strategies to slow decline, optimize function (especially cognitive function), and nurture as much independence as possible in the person with the diagnosis of AD. Further, there is a need for better therapies to improve symptoms, to prevent cognitive dysfunction by optimizing a healthy lifestyle, or to alter the disease course even at later stages of the disease. High priority will be given to novel therapeutic approaches.

Focus Area 5.4 Understanding co-morbidities and other factors that contribute to progression of AD. There is increasing evidence that co-morbidities may dramatically alter the course of AD. Further, other events, such as infection, surgery, acute and repeated head traumas, and hospitalization, appear to accelerate cognitive decline. Conversely, there are factors that may slow progression (e.g., physical exercise, good nutrition, appropriate hydration, avoidance of anticholinergics and benzodiazepines, treatment of cardiovascular conditions, and healthy sleep). High priority will be given to applications that can provide fundamental insights into how co-morbidities and other potentially modifiable risk-factors contribute to cognitive decline and dysfunction.

Priority Area 6:

Objectives: This FOA aims to stimulate the discovery and validation of the impact of daily multi-vitamin use on cognitive function. The major overall goal of this FOA is to foster novel ideas relating to the impact of daily multi-vitamin use on the improvement of cognitive function and any associated health care cost impacts on Medicaid Long Term Care or state prison populations over the age of 65. Consortium grants are encouraged for maximum return on results. Priority will be given to applications that involve populations that have been historically underrepresented in research.

3. Grant Categories

The Florida Department of Health (Department) anticipates making awards from the following types of grant categories:

- **Consortium Grant:** Stimulate a consortium of clinical, basic, translational and underrepresented research institutions/centers to conduct high quality grant-supported

research. The consortium should involve partnerships to be developed among investigators across the State of Florida, with the award made to the lead organization. The lead organization of the consortium must perform a substantive role in conducting the planned research including providing oversight of all scientific, programmatic, financial, and administrative matters related to the grant. The collaborating organizations must have well-defined roles that contribute to the common scientifically rigorous research goals, and include sound background information, hypotheses, protocols, and promising practices that address clearly one or more areas of research interest. A letter of commitment from all collaborating organizations is required. The consortium must support the exploration of the focus areas listed within Priority Areas 1 and 3. Grants may range from discovery science to more mature projects that are attempting to advance a therapeutic approach or concept.

- Research organizations are eligible to **apply for no more than one Consortium Grant**.
 - The PI must be a full-time faculty member at the lead institution.
 - The application must include at least **three** collaborating institutions. The lead institution must be an existing established university or research institute.
 - Maximum award amount will be up to \$750,000 per award.
 - Maximum duration to complete the grant will be up to four years. **Grant duration is contingent upon legislative spending authority from fiscal year to fiscal year.**
- **Standard Grant:** Research projects that are fully developed, scientifically rigorous, and include sound background information, hypotheses, and promising preliminary results or supporting data.
 - Research organizations are eligible to **apply for no more than seven Standard Grants** that address the five priority areas listed in Section 2, Priority Areas. Organizations choosing to submit more than one Standard Grant application may have **no more than three applications in a single Priority Area**.
 - Maximum award amount will be up to \$350,000 per award.
 - Maximum duration to complete the grant will be up to four years. **Grant duration is contingent upon legislative spending authority from fiscal year to fiscal year.**
- **Pilot Grant:** Exploratory, novel studies that break new ground or extend previous discoveries toward new directions or applications. No preliminary data are required but may be included if available.
- - Research organizations are eligible to **apply for no more than four Pilot Grants** that address one of the five Priority Areas listed in the previous section. If an institution submits more than one Pilot Grant application, **no more than two applications may be submitted within the same Priority Area**.
 - Maximum award amount will be up to \$100,000 per award.
 - Maximum duration to complete the grant will be up to two years. **Grant duration is contingent upon legislative spending authority from fiscal year to fiscal year.**
- **Postdoctoral Research Fellowship Grant:** Supports the career development of individuals who have made a commitment to focus their research endeavors on research

oriented to clinical service, evaluation, neurochemistry, neurosciences, neuromedicine, neurotherapeutics, neuropharmacology, neuropathology, etc.

- - Research organizations are eligible to apply for **no more than three Postdoctoral Research Fellowship Grants**. Organizations choosing to submit two or more Postdoctoral Research Fellowship Grant **applications must assure that they address different focus areas (1-4) listed under Priority Area 5**.
 - Maximum award amount will be up to \$100,000 per award.
 - Maximum duration to complete the grant will be up to two years. **Grant duration is contingent upon spending authority from fiscal year to fiscal year.**

To summarize, the **maximum total number of applications an organization may submit is 15** in the following categories:

- **Consortium Grant:** One application (in Priority Area 1 and 3; only **one** application per institution)
- **Standard Grant:** Seven applications (no more than **three** applications per Priority Area)
- **Pilot Grant:** Four applications (no more than **two** applications per Priority Area)
- **Postdoctoral Research Fellowship Grant:** Three applications (in Priority Area 5, each grant in different Priority Area 5 Focus Areas)

All applications must be different. Organizations may not submit the same application in different grant categories. For example, organizations may not submit the same project for a Standard Grant and a Pilot Grant.

Institutions must specify the appropriate grant Category and Priority Area for each application. Applications submitted in incorrect Priority Areas will be ineligible for funding or peer-review.

4. Highlights

- **All awards in response to this FOA are subject to the availability of funds and spending authority provided by the Florida Legislature. By submitting a grant application pursuant to this FOA, all applicants acknowledge and consent to this condition.**
- Applications conducting research with Department data must include a letter of support from the program office that houses the data. For example, an applicant conducting research using data from the Bureau of Vital Statistics must include a letter of support from that Bureau.
- Applications will only be accepted through the online application system.
- There is a defined question and answer timeframe as indicated in **Table 1. Schedule of Important Dates**. To ensure equal access by all applicants to questions and answers, all questions must be submitted in writing. Answers to questions will be published according to the schedule indicated in Table 1. Questions that are received after the timeframe deadlines as indicated in Table 1 will not be answered.

- For research, especially involving human participants or animals, grantees are required to obtain and maintain approval or receive a signed waiver from an IRB accredited by the Association for Accreditation of Human Research Protection Programs (AAHRPP), or from an Institutional Animal and Core Use Committee (IACUC) within 60 days of notice of award. Grantees should be prepared to start the regulatory review process at their institution immediately upon being notified of an award. Grantees are required to follow Department policies for reporting unanticipated problems and non-compliance involving research to the Department. Department policies comply with Title 45 Code of Federal Regulations, Part 46. For more information about reporting requirements, refer to the U.S. Department of Health and Human Services' Office of Human Research Protections website at <http://www.hhs.gov/ohrp/>. All research that requires recruitment of participants should include the research project on the Alzheimer's Association TrialMatch website (<https://www.alzheimers.gov/clinical-trials/trialmatch>).
- The Program will pay a proportional percentage of the base salary (based on effort) of any personnel named on the grant application. The **maximum annual base salary** used in calculating these payments must not exceed the Executive Level II annual salary rate of the Federal Executive Pay Scale that is in effect as of the application submission date. See Section [II](#). Eligibility and Application Requirements, 7. Definitions, for more information about the Federal Executive Pay Scale.
- Applicants are encouraged to check the Program website (<http://www.floridahealth.gov/provider-and-partner-resources/research/funding-opportunity.html>) regularly throughout the application, peer review, and award processes for Program announcements, addendums, and answers to programmatic questions.
- All materials submitted to the Department are subject to the provisions of Article 1, Section 24, Florida Constitution and Chapter 119, Florida Statutes, Florida's public records law. These laws grant a right to inspect any public record to anyone upon request. All Program materials, including applications, are public record. Refer to Section [II](#). Eligibility and Application Requirements, 6. Requirements for Protecting Intellectual Property, for instructions on how to properly identify confidential/proprietary information.
- The Grant Administration Manual is an important reference document for grant awardees. It contains Department policies as well as the procedures necessary for compliance with those policies and is organized around a typical grant lifecycle. The Manual can be found at <http://www.floridahealth.gov/provider-and-partner-resources/research/grant-programs-resources/forms-library.html>.
- After awards are made, each grantee must sign a contract, called the "Terms and Conditions," agreeing to certain legal requirements of the award. The "Terms and Conditions" are non-negotiable and acceptance is required as part of the grant award process. The Department reserves the right to change or modify the "Terms and Conditions" as needed. By submitting a grant application pursuant to this FOA, all applicants acknowledge this requirement. The "Terms and Conditions" also include the post-award schedule of deliverables.

Schedule of Important Dates

Table 1. Schedule of Important Dates		
ACTIVITY	DATES	IMPORTANT INFORMATION
Funding Opportunity Announced	On or around August 15, 2024	Located on the Program's website at: http://www.floridahealth.gov/provider-and-partner-resources/research/funding-opportunity-announcements/index.html
Letter of Intent Opens (REQUIRED)	By 5: 00 p.m., EST August 19, 2024	Letter of Intent must be submitted in the online system located on the Program's website. Applications without a Letter of Intent by the deadline are not eligible and will not be considered.
Informational Webinar	11: 00 a.m., EST August 21, 2024	Program staff will conduct an informational webinar about the current FOA and answer participant questions in real time.
Written questions accepted	Questions may be submitted any time until 5: 00 p.m. EST August 26, 2024	Email questions to: Research@flhealth.gov
Answers posted to written questions	By August 27, 2024	Questions and answers will be published on the Program's website in two groups as they come in.
Letter of Intent due (required)	Letter of Intent must be submitted by 5: 00 p.m. EST August 28, 2024	Letter of Intent must be submitted in the online system located on the Program's website. Applications without a Letter of Intent by the deadline are not eligible and will not be considered.

Main application opens	Anticipated date: September 17, 2024	Applications must be submitted in the online system located on the Program's website.
Applications due	Applications must be submitted before 5: 00 p.m. EST October 1, 2024	Applications must be submitted using the online system available on the Program's website. Applications must be submitted before the deadline. Applications being edited will not be accepted after the deadline.
Awards Announced	Anticipated date: December 13, 2024	Award letters and Terms & Conditions will be emailed to the Sponsored Research Official and the Corresponding Principal Investigator.
New Awardee Orientation Webinar	December 17, 2024	Discussion on Budget revisions and orientation, open to all Principal Investigators and Administrative staff
Grant Budget Revisions	December 20, 2024	Budget Template Form located in the PeerNet System Grant Forms Library

<p>Institutional Reviews Due (if applicable)</p>	<p>Immediately after award notification, grantees should submit application(s) for all institutional authorizations including, but not limited to the IACUC, IRB and Radiation Safety Review. Project work may not begin until documentation of all approvals is provided. The documentation of institutional approval(s) must have the same project title and must be signed by the Review Board chairperson or organizational representative. Projects which include research participant incentives in their budgets must receive approval from an accredited IRB. If the research proposal is selected for Department funding, the original IRB approval protocol and consent form must be submitted to the Department before any incentives are distributed. These documents will be kept in the grant management folder at the Department.</p>	<p>Grantees should be prepared to start the regulatory review process at their institutions immediately upon being notified of award.</p>
<p>Grants begin</p>	<p>Anticipated Date: On or about March 1, 2025</p>	<p>Contingent on verification of all eligibility requirements and regulatory approvals.</p>
<p>Proposal Evaluation Summaries Available to Applicants</p>	<p>Anticipated Date: On or about January 20, 2025</p>	<p>Individual evaluation reports will be provided to applicants. Applicants will be notified via e-mail with their evaluation report is available.</p>

Changes to dates or other requirements will be posted to the Program website. Applicants should monitor the program website (<http://www.floridahealth.gov/provider-and-partner-resources/research/funding-opportunity.html>) for changes and announcements.

II. ELIGIBILITY AND APPLICATION REQUIREMENTS

1. Alzheimer's Disease-Relatedness

All applicants must clearly demonstrate how the proposed project is relevant to AD. Proposals that do not or cannot demonstrate a close relationship with advancing progress toward etiology, prevention, diagnosis, treatment, care management, and cure of AD will not be funded.

2. Eligibility Requirements

A. Eligible Applicants

According to section 381.82(2)(b), Florida Statutes, applications for AD research funding under the Program may be submitted by a PI from any university or established research institute in Florida. Established research institutes, as defined on page 28 of this Funding Opportunity Announcement, do not include Veteran's Administration (VA) hospitals. Although the PI submitting the application may not be a full-time or part-time employee of a VA hospital, the grant application may list collaborators such as a Co-PI from a VA hospital among the key personnel. The PI must have the skills, knowledge, and resources necessary to carry out the proposed research as well as possess personal interest, commitment, and expertise consistent with the goals of the Ed and Ethel Moore AD Research Program. The PI must hold a research or health professional doctoral level degree, i.e., a MD, PhD, MD/PhD, DO/PhD, DO, DNS/DNS(c) (Doctor of Nursing Science) or equivalent. The PI must be in good standing and judged to have the appropriate training, level of authority and responsibility to direct the research program or project outlined in the grant application to the Ed and Ethel Moore AD Research Program. The PI is responsible to ensure the proper conduct of the research program or project, comply with all the requirements of the Ed and Ethel Moore AD Research Program, and submit all required reports. The PI is the one individual designated by the applicant organization to direct the project to be supported by the grant, is responsible and accountable to the applicant organization officials for the proper conduct of the project. The PI must have research experience and the time commitment to supervise the project directly and in person.

An application submitted by any existing established university or research institute which collaborates with a clinical organization, or community-based or hospital-based, free-standing Memory Disorder Clinic/Center must show a clear and high-quality research relationship, collaboration, infrastructure, and protocol in the application. Such an application must identify clearly who is the one PI designated by the applicant organization as legally responsible to direct the grant project. The PI is responsible and accountable to the applicant organization officials for the project's scientific and technical direction as well as the proper conduct of the project. There may be multiple collaborators on a project, but there must be only one PI.

To be eligible as a PI at an eligible institution, the individual must be a full-time faculty member or researcher employed by the lead institution by the time the application is submitted and may have a joint appointment by more than one research institution that totals full time employment. Temporary faculty members/researchers, even though full-time, are not eligible to apply. The license of the PI must be up to date and in good standing in the State of Florida. Only U.S. citizens or permanent residents may be principle or co-PI. Non-PIs may be employed on the grant with an authorized visa (i.e., J-1 visa). Unauthorized aliens shall not be employed pursuant to §274A(e) of the Immigration and Naturalization Act (8 U.S.C. 1324a), section 101 of the Immigration Reform and Control Act of 1986, and Florida Executive Order 11-02. Grant applications failing to meet the eligibility requirements will be disqualified.

B. Letter of Intent

Submission of a Letter of Intent (LOI) is required prior to submission of an application. The LOI must be submitted by the applicant in the online application system. Applicants must obtain an approval letter from their Office of Research (or Sponsored Research). This letter must state that the LOI has been reviewed and approved by the Office of Research and include the signature of the Sponsored Research Official. Applicants will then upload a scanned copy of the approval letter to the online application system when they submit their LOI. For collaborative applications, the applicant from the lead organization is required to submit the LOI. The information in the LOI allows Department staff to estimate the potential review workload and plan for the review. Applications will not be accepted if the applicant has not submitted a LOI by the deadline listed in Table 1. However, applicants who submit a LOI are not bound to apply, and a decision to submit a LOI and not apply will not affect eligibility for future funding opportunity announcements or be considered by peer reviewers in future funding applications. Researchers must apply under the same title that was specified in the LOI. In addition, the PI may not change between the LOI and the application.

Prospective applicants must submit a LOI through the online system that includes all the following items of information:

1. Name, address, telephone number, email address of the Principal Investigator.
2. Names of other research personnel.
3. Name, address, telephone number, email address of the Sponsored Research Official.
4. Lead organization.
5. Collaborating institutions and collaborating research personnel if any.
6. Descriptive title of proposed research.
7. Research Priority Area.
8. Grant category.
9. General Audience Abstract (no more than 500 words).
10. Key Words (no more than five words)
11. Signed Approval Letter from the Principal Investigator's Office of Sponsored Research.

C. Guidelines for Alzheimer's Disease Research Grant Advisory Board Member Participation

The Florida Alzheimer's Disease Research Grant Advisory Board (Board) has statutory conflict of interest obligations regarding the participation of its members in Ed and Ethel Moore Alzheimer's Disease Research Program grants and grant applications.

Board members shall not:

- Participate in any discussion or decision of the Board or a panel with respect to a research proposal by any firm, entity, or agency with which the member is associated as a member of the governing body or as an employee or with which the member has entered a contractual arrangement.
- Receive any form of financial compensation from a Program grant award.
- Participate in any named role on a proposed Program grant project in this FOA.
- Advise applicants regarding the preparation of a specific Program grant application.
- Answer any programmatic questions (eligibility, content of the FOA, competition procedures, etc.).
- Violate any provision of Chapter 112, Part III, Florida Statutes.

Violations of these restrictions may result in the disqualification of an applicant for this competition. For a list of Board members, refer to the program website: [Ed and Ethel Moore Alzheimer's Disease Research Program Website](#).

D. Types of Applications and Overlap Limits

The Department will accept the following types of applications:

- **New application:** An application that has not been submitted to the Program in a previous competition.
- **Revised application:** An application that was submitted to the Ed and Ethel Alzheimer's Disease Research Program, but not funded. Applications must identify areas that have been revised from the initial submission.

Applicants must ensure that their proposed project does not duplicate or significantly overlap, scientifically or financially, with other projects in which they or any key personnel are involved. Overlap, whether scientific or financial, or commitment of a project member's effort greater than 100 percent is prohibited.

The Principal Investigator may:

- Serve as a co-PI or other role on other applications.

The Principal Investigator shall not:

- Submit the same project/research to the Program that is also being submitted by another investigator regardless of the grant mechanism.
- Submit an application that was reviewed during a previous funding cycle and did not receive funding unless the applicant has followed the instructions for submitting a revised application outlined above.

- Submit two or more applications in which they are listed as the PI to the Program during the same FOA.

3. Required Grant Application Components

A complete Grant application package must contain all required items listed in [Table 2](#).

Table 2. Application Components	
The online application will prompt applicants of required fields and word limits for each section.	
Category	Comment
General Project Information	Required. Identifies general project information, the applicant organization, and the principal investigator.
Fellowship Plan	Required (if applicable). Describe a plan: (1) that shows a logical progression from prior research and training experiences to the patient-centered clinical and research career development experiences that will occur during the award period and then to independent investigator status; and (2) that justifies the need for further career development to become an independent investigator.
Human Subjects	Required (if applicable). Describe protections for human subjects involved in the research.
Vertebrate Animals	Required (if applicable). Describe protections for animals involved in the research.
Recombinant DNA Molecules	Required (if applicable). Describe use of recombinant DNA molecules involved in the research.
Survey Instruments	Required (if applicable). Survey Instruments must be uploaded as a single document.
Table, Image, or Graph	Optional. Upload a single document containing images, graphs, and figures. (There is no page limit on the number of images, graphs, and figures). Images, graphs, and figures cannot appear in the text of the application but must be uploaded separately in this section. Figure legends need to be included in the document.
Table 2. Application Components	
The online application will prompt applicants of required fields and word limits for each section.	
Category	Comment
Budget Template	Required. The budget must explain the planned spending. See appendix for template. The budget module must be edited and submitted within the online application system. When applications involve collaborations with different universities or research institutions, the lead institution should complete the budget form and include collaborating institutions as a contractual expense.
Collaborator Information	Required. Identifies all key personnel.
Biographical Sketch	Required. Bio-sketches of key personnel must be uploaded as a single document in the format specified in the online system.

Consultants	Required (if there are consultants). Letters from all consultants confirming their roles in the project, including the rate/charge for consulting services, must be uploaded as a single document.
Research/Project Plan	Required. Describe the specific aims including the significance, innovation, and approach. Provide a bibliography of any references cited and list facilities and other resources.
General Audience Abstract	Required. Explains the proposed project in lay terms, including its relationship to the Priority Areas listed in this FOA.
Scientific Abstract	Required. This is the scientific description of the project.
Health Impact	<p>Required. Applications must describe how the proposed project impacts the health of Floridians. Health impact means the ability of the research to reduce morbidity and mortality from AD. Applications must describe how the results of the research can provide information and evidence for changes in policy, or improve health service delivery and quality of care, or improve disease prevention through improvements in health literacy and changes in behavior within a certain amount of time.</p> <p>Do not consider possible long-range effects of applying knowledge gained in the research or the ability of the research to support future research grant applications or publications or patents as a health impact that may result from the research.</p>
Alzheimer's-Relatedness	Required. Provides a clear explanation of how the project is related to Alzheimer's Disease.
Letters of Support	Required. (if applicable) If applying for a fellowship grant, signed letters of support confirming participation and describing specific roles must be uploaded. If applying for a grant involving Department data, a signed letter of support from the program office, which houses the data, must be uploaded. Upload as a single document. (There is no page limit on the number of letters of support).
Reportable Financial Interests	Required. The Principal Investigator must disclose any financial interests that the researcher, the researcher's immediate family, or any other personnel on the project (sub-investigators and research staff) and their immediate families, have related to the research.

Table 2. Application Components

The online application will prompt applicants of required fields and word limits for each section.

Category	Comment
<p>Applicants are discouraged from submitting information considered proprietary unless it is deemed by the applicant to be essential for proper evaluation of the application.</p> <p>If the application contains information that the applicant believes constitutes trade secrets or proprietary information or is protected by a specific statutory exemption; it should be limited to the Research Project Plan section. The applicant must CLEARLY identify the information with [brackets] and a footnote that specifies the law that makes the document or information exempt from the public records laws. If a public records request is made involving documents with declarations of confidentiality, the Department will notify the applicant so that he/she may defend the claim in circuit court. The Department will not provide legal representation to assert a confidentiality claim when a public record request is made.</p>	

4. Allowed and Disallowed Costs

The following information explains direct and indirect costs allowed by the Department, as well as disallowed costs.

A. Allowed Direct Costs

Allowed direct cost expenses must be directly related to the project and may include:

- Salaries, including up to a three percent increase per year.
- Background Screening: Level II (if required) should be included under other expense category.
- Tuition (documentation of courses must be submitted with quarterly financial expenditure report).
- Fringe benefits.
- Supplies.
- Equipment, including CT, MRI, or other imaging systems, and improvements to existing systems. For the purposes of this FOA, "equipment" refers to items with a purchase price of over \$5,000.00 and with a useful life of over one year.
- Lab services.
- Travel will be reimbursed at no more than the State of Florida travel reimbursement rates. Current State of Florida reimbursement rates can be found in section 112.061, Florida Statutes. To implement appropriations in the General Appropriations Act for state travel and notwithstanding s. 112.061, Florida Statutes, costs for lodging associated with a meeting, conference, or convention organized or sponsored in whole or in part by a state agency or the judicial branch may not exceed \$175 per day.
- Consultant costs, provided they do not exceed 10 percent of the total budget.
- Patient-care costs.
- Animal-care costs.
- IRB or IACUC fees.
- Consortium or contractual costs.
- Fees to obtain data from a health registry (e.g., vital statistics.)
- Research Participant Incentives (gift cards, checks, or cash.)
- Indirect costs up to 15 percent may be included in direct cost categories for services, functions, or activities that are directly necessary for this grant.

Research Participant Incentives can be given in the form of cash, check, or gift card. Participant payment logs must be kept using de-identified participant information. Gift cards should not be purchased in bulk as tracking and inventory control can be difficult. Gift cards should be purchased as needed. If awarded, the original approved IRB protocol and consent form must be submitted to the Department before any participant incentive charges may be made to the grant. Grants executed in FY 21/22 and later will comply with the approved IRB protocol. Each grant executed in FY 22/23 will reference the approved IRB protocol in the method of payment section of each grant agreement.

Administrative costs may be included in direct cost categories, but only under two conditions:

- The services, functions, or activities are directly necessary for this grant, and
- These administrative costs have not been included in the calculation of the indirect costs.

The Program does not prohibit administrative costs as part of direct costs, but to be allowable, they must meet both above conditions. All direct costs must be specifically and directly related to the project, necessary for the project's completion, and adequately justified. Pay particular attention to these criteria with costs such as copying charges, telephone and Internet charges, maintenance contracts, etc.

Maximum Annual Base Salary Calculations:

The Program will pay a proportional percentage of the base salary (based on effort) of any personnel named on the application for this grant. The maximum annual base salary used in calculating these payments must not exceed the Executive Level II annual salary rate of the Federal Executive Pay Scale that is in effect as of the application submission date. See Section Eligibility and Application Requirements, 7. Definitions, for more information about the Federal Executive Pay Scale. This salary cap excludes fringe benefits, facilities and administrative (F&A) expenses; and excludes any income that an individual may be permitted to earn outside of the duties to the applicant organization. This provision is consistent with the NIH salary limitations on grants, cooperative agreements, and contracts.

Work Must Occur in Florida:

Activities funded through this competition must occur in Florida. All work (effort) must occur, and funds must be spent in Florida at the applicant organization and any collaborating entities. However, the Department may make exceptions if the service is essential and only provided outside the state, and if the amount is less than 10 percent of the requested amount.

Subcontracts must be pre-approved in the Public Health Research Program Budget Template (Attachment V). The Budget Narrative must justify the purpose of the subcontract and whether this is the only vendor that can perform the services, regardless of if they are in-state or out-of-state.

B. Allowed Indirect Costs

Indirect costs (also referred to as IDC, F&A, or administrative costs) may not exceed 15 percent of the direct costs requested.

C. Disallowed Costs

All direct costs must be specifically and directly related and allocated to the project, necessary for the project's completion, adequately justified, and made during the active grant period. Any other costs are disallowed. Additionally, the following items shall NOT be paid for with grant funds:

- Department personnel
- Construction, renovation, or remodeling
- International travel (including Canada)
- Vehicles
- Entertainment
- Employment subsidies
- Dues/Membership fees

- Lobbying
- Meals/Food (other than as part of travel costs)
- Malpractice insurance premiums

5. Inquiries and Contacts

A. Programmatic Questions about This Funding Opportunity

This FOA is issued by the Department. The Public Health Research Unit manages the FOA and is responsible for answering all applicant questions. Applicants and persons acting on their behalf may contact the Department in writing via email as indicated below regarding programmatic issues. Applicants who attempt to contact the Alzheimer's Disease Research Program Grant Advisory Board members regarding this FOA may have their applications disqualified.

To ensure equal access by all applicants to questions and answers, all programmatic questions must be submitted in writing via email to research@flhealth.gov. Answers to questions will be available on the program website. Answers to submitted questions will be posted in groups as they are received and published on the website, according to the schedule in Table 1. Schedule of Important Dates.

B. Technical Questions about the Online Application

Direct all questions about the online application process and related issues (e.g., username and password problems) to research@flhealth.gov.

The Department recommends that applications be submitted early. Applications submitted past the deadline will not be considered, regardless of the reason.

6. Requirements for Protecting Intellectual Property

Submitted materials are subject to the provisions of Article I, Section 24, Florida Constitution and Chapter 119, Florida Statutes, Florida's public records law. These laws grant the right to any person to inspect any public record. Some documents and information that are exempt from the public records laws. All application materials are public record unless the applicant can show how they are exempt.

Applicants are strongly discouraged from submitting information considered proprietary unless it is deemed by the applicant to be essential for proper evaluation of the application. If the application contains information that the applicant believes constitutes trade secrets, intellectual property, proprietary information, or information protected by a specific statutory exemption, it should be limited to the Main Application Body. The applicant must clearly identify the confidential information with [brackets].

If a public records request is made involving documents with declarations of confidentiality, the Department will notify the applicant so that he/she may substantiate and defend the claim. The Department will not provide legal representation to assert a confidentiality claim.

7. Definitions

Alzheimer’s Disease: According to the National Institutes of Health, “Alzheimer’s disease is an irreversible, progressive brain disorder that slowly destroys memory and thinking skills, and eventually the ability to carry out the simplest tasks. In most people with Alzheimer’s, symptoms first appear in their mid-60s. [. . .] Alzheimer’s disease is currently ranked as the sixth leading cause of death in the United States, but recent estimates indicate that the disorder may rank third, just behind heart disease and cancer, as a cause of death for older people.”

Alzheimer’s Disease Research Grant Advisory Board (The Board): The Board was created per Section 381.82(3), Florida Statutes. According to statute, the Board “shall consist of two geriatric psychiatrists, two geriatricians, two neuroscientists, and three neurologists.” Board members “must have experience in Alzheimer’s disease or related biomedical research.” The board shall consider applications for program funding and make recommendations to the State Surgeon General by December 15 of each year.

Business entity: Per Section 606.03(1), Florida Statutes, this means any form of corporation, partnership, association, cooperative, joint venture, business trust, or sole proprietorship that conducts business in Florida.

Collaborator: An individual involved with the PI in the scientific development or execution of the project. These individuals typically devote a specific percent of effort to the project and are identified as key personnel. The collaborator may be employed by, or affiliated with, either the Grantee institution or an institution participating in the project under a consortium or contractual agreement.

Commercialization: The process of developing markets and producing and delivering products or services for sale (whether by the originating party or by others). As used by the Program, commercialization includes both government and non-government markets.

Consortium: A consortium should involve partnerships to be developed among investigators across the state of Florida, with the award made to the lead organization. The lead organization of the consortium must perform a substantive role in conducting the planned research including providing oversight of all scientific, programmatic, financial, and administrative matters related to the grant. The collaborating organizations must have well-defined roles that contribute to the common scientifically rigorous research goals, and include sound background information, hypotheses, protocols, and promising practices that address clearly one or more areas of research interest. A letter of commitment from all collaborating organizations is required.

Contractual Agreement: An agreement whereby a project is carried out by the Grantee and one or more other organizations that are separate legal entities. In this arrangement, the Grantee contracts for the performance of a substantial and/or a significant portion of the activities to be conducted under the grant

Consultant: An individual hired to give professional advice or services for a fee, normally not as an employee of the hiring entity. Consultants may also include firms that provide paid professional advice or services.

Community-Based Participatory Research (CBPR): A collaborative approach to research that involves all partners in the research process and recognizes the unique strengths that each brings. CBPR begins with a research topic of importance to the community (which can be self-defined, regional, or by interest) and has the aim of combining knowledge with action and achieving social change to improve health outcomes.

Cooperative Agreement: A support mechanism that will have substantial scientific and/or programmatic involvement. Substantial programmatic involvement means that after award, scientific or project staff will assist, guide, coordinate, or participate in programmatic activities beyond the normal stewardship responsibility in the administration of grants. Proposed cooperative agreements will be published as policy announcements, program announcements, or requests for applications.

Department: The Florida Department of Health works to protect, promote & improve the health of all people in Florida through integrated state, county, and community efforts.

Development: The systematic application of knowledge toward the production of useful materials, devices, and systems or methods, including design, development, and improvement of prototypes and new processes to meet specific requirements.

Eligible Institution: Any public university, non-public institution, or established research institute (see specific definitions of each) in Florida.

Established Research Institute: An established research institute eligible for Program funding is an organization that is any Florida nonprofit covered under Chapter 617, Florida Statutes, with a physical location in Florida, whose stated purpose and powers are scientific, biomedical or biotechnological research and/or development and is legally registered with the Florida Department of State, Division of Corporations. For purposes of this competition, federal government and nonprofit medical and surgical hospitals including Veteran's Administration hospitals are not considered eligible research institutes.

Feasibility: The practical extent to which a project is capable of being successfully performed within the requested time and for the awarded money.

Federal Executive Pay Scale, Executive Level II: The U.S. Office of Personnel Management establishes executive pay schedules each year normally around the first month of the calendar year. To view the current Executive Level II, pay scale, visit the website of the U.S. Office of Personnel Management at <http://www.opm.gov/oca/> and search for executive schedule.

Full-time Equivalent (FTE): The definition of an FTE must be in accordance with the institution's policy, used consistently by the institution regardless of the source of support, and may be different in terms of actual months per year or days per week at the applicant institution.

Full-time Faculty: Full-time Faculty positions are defined as teaching, clinical, and research appointments carrying classroom teaching, laboratory teaching, clinical teaching or service, or research assignments equal to at least nine months per fiscal year or 0.75 FTE. This includes tenured, tenure-track, and non-tenure track appointments.

Indirect Costs: Indirect costs up to 15 percent may be included in direct cost categories for services, functions, or activities that are directly necessary for this grant.

Institutional Base Salary: The annual compensation that the applicant institution pays for an employee's appointment, whether that individual's time is spent on research, teaching, patient care, or other activities. Base salary excludes any income that an individual may be permitted to earn outside of duties to the applicant institution. Base salary may not be increased because of replacing institutional salary funds with grant funds.

Institutional Review Board (IRB): A committee that reviews research involving human subjects to determine if research complies with law, including but not limited to 45 CFR 46, and 21 CFR 50, 56, 312 and 812 as applicable.

Key Personnel: Key personnel are defined as, and should be limited to, individuals who contribute to the scientific development or execution of the project in a substantive way, whether salaries are requested. Only U.S. citizens or permanent residents may be principle or co-PIs. Non-PIs may be employed on the grant with an authorized visa (i.e., J-1 visa).

Nonpublic Institutions: Nonpublic institutions in Florida operating under Chapter 1005, Florida Statutes, are eligible. For the purposes of the Program, any branch campuses, centers, or other affiliates of a nonpublic institution are considered one and the same with that institution. Where the number of applications is limited, the institution and its branch campuses, centers, or other affiliates must coordinate submission(s) to comply with the limitation.

Overlap, Commitment: Commitment overlap occurs when any project staff has time commitments exceeding 100 percent. This is the case whether or not the grant includes salary support for the effort. While information on other support is only requested for the PI, no individual on the project may have combined commitments more than 100 percent.

Overlap, Financial: Financial overlap occurs when duplicate or equivalent budget items (e.g., equipment, salary) are requested in an application but are already funded or provided for by another source.

Overlap, Scientific: Scientific overlap occurs when: a) substantially the same research is funded by two or more different funding sources, or b) a specific research objective and the research design for accomplishing that objective are the same or closely related in two or more awards, regardless of the funding source.

Principal Investigator: The PI must have the skills, knowledge and resources necessary to carry out the proposed research as well as possess personal interest, commitment and expertise consistent with the goals of the Ed and Ethel Moore Alzheimer's Disease Research Program. The PI must hold a research or health professional doctoral level degree, i.e., a MD, PhD, MD/PhD, DO/PhD, DO, DNS/DNS(c) (Doctor of Nursing Science) or equivalent in comparable health science. The PI must be in good standing and judged to have the appropriate training, level of authority and responsibility to direct the research program or project outlined in the grant application to the Ed and Ethel Moore Alzheimer's Disease Research Program. The PI is responsible to ensure the proper conduct of the research program or project, comply with all of the requirements of the Ed and Ethel Moore Alzheimer's Disease Research Program, and submit all required reports. The PI is the one individual designated by the applicant's organization to direct the project to be supported by the grant and is responsible and accountable to the applicant's organization officials for the proper conduct of the project.

The PI must have research experience and the time commitment to supervise the project directly and in person. The PI is responsible and accountable to the applicant's organization officials for the project's scientific and technical direction as well as the proper conduct of the project. There may be multiple collaborators on a project, but there must be only one PI. To be eligible as a PI at an eligible institution, the individual must be a full-time faculty member or researcher employed by the lead institution by the time the application is submitted which may include a joint appointment by more than one research institution that totals full time employment. Temporary faculty members/researchers, even though full-time, are not eligible to

apply. The health-related license of the PI must be up to date and in good standing in the State of Florida. Only U.S. citizens or permanent residents may be principle or co-PIs. Non-PIs may be employed on the grant with an authorized visa (i.e., J-1 visa). Unauthorized aliens shall not be employed pursuant to §274A(e) of the Immigration and Naturalization Act (8 U.S.C. 1324a), section 101 of the Immigration Reform and Control Act of 1986, and Florida Executive Order 11-02.

Program: In this context, “Program” refers to the Ed and Ether Moore Alzheimer’s Disease Research Program established in section 381.82, Florida Statutes. The purpose of the Program is to fund research leading to prevention of, or a cure for, Alzheimer’s disease by pursuing the following goals: a) Improve the health of Floridians by researching better prevention and diagnoses of, and treatments and cures for, Alzheimer’s disease; b) Expand the foundation of knowledge relating to the prevention, diagnosis, treatment, and cure of Alzheimer’s disease; and c) Stimulate economic activity in Florida in areas related to Alzheimer’s disease research.

Public University: A public (state) university is defined in section 1000.21, Florida Statutes, except as otherwise specifically provided in that Statute; are the 12 named public, postsecondary institutions and any branch campuses, centers, or other affiliates of the institution. For purposes of the Program, any branch campuses, centers, or other affiliates of a public university are considered one and the same with that university. Where the number of applications is limited, the university and any branch campuses, centers, or other affiliates must coordinate submission(s) to comply with the limitation.

Subcontracting: A contract between the awardee and a third party to perform all or some of the work on the awardee’s behalf. This definition does not apply to an awarded consortium unless that consortium is contracting with a third party outside of the organization to perform some or all the work on its behalf.

III. INSTRUCTIONS FOR APPLICATION PREPARATION AND SUBMISSION

Applications will only be accepted through the online application system found on the Program’s website: <http://www.floridahealth.gov/provider-and-partner-resources/research/funding-opportunity.html>.

Application materials not submitted in the specified manner and in the specified format will be disqualified from competition.

Required signature pages such as budgets and letters of support, must be included in the appropriate section of the application as indicated in the online system. Online applications without scanned copies of these pages will be disqualified.

Other documentation and materials such as biographical sketches and other support must be converted to electronic format and placed in the appropriate section of the online application.

Applications will be evaluated on the materials in the application, and other sources of information will not be considered.

A. Online Registration and Application Submission

The online system will be available to accept applications for this FOA on the date published in Table 1. Schedule of Important Dates.

To complete the online application process:

1. Applicants must register to access the online application and forms. Register for an online application on the program website (<https://peernet.orau.org/Intake/Submission/948b695c-ad96-e911-8142-0050568131c9>) and complete the brief project profile. Registration will be acknowledged with an email message containing login instructions and a username and password. Reference <http://www.floridahealth.gov/provider-and-partner-resources/research/funding-opportunity.html> for frequently asked questions (FAQs) and additional information.
2. Complete the online application form. Deviations may be grounds for the Program to reject the entire application. Special formatting, scientific notation, pictures, and objects may be included in these documents. However, within the online application form fields such as the Project Title, General Audience Abstract and the Scientific Abstract, use only conventional alphanumeric letters and numbers (i.e., ASCII text) with no drawings, special characters, or symbols.
3. An application cannot be changed after an application is submitted. Errata sheets or replacement files will not be accepted once an application is submitted.

B. General Application Guidelines

1. Applications must be in English.
2. The entire text of all documents uploaded into the online application must be single spaced in an easily readable font. Use standard 11-point type for the text, and no less than 10-point type for tables figures and legends. Margins on all applicant created documents should be at least one inch (excluding required headers and footers). Do not use photo reduction for scanned items. Use black type for all text. The application must contain only materials that, when scanned or converted to PDF format, are clear, sharp, and easy to read.
3. All applications must be self-contained within specified page limits. Unless otherwise specified in this document, Internet website addresses (URLs) may not be used to provide information necessary to the review because reviewers are under no obligation to view the Internet sites.
4. Before it can be submitted, the application must contain all the required sections identified in Table 2. Application Components. Uploaded files should be titled by the categories listed in the table.
5. Applications must comply with space limitations specified in the online application. Appendices are not allowed.

IV. AFTER APPLICATION SUBMISSION

1. Changes to a Submitted Application

It is the responsibility of the applicant to ensure that a complete application is submitted by the applicant before the date and time specified in [Table 1](#). Schedule of Important Dates. The Department does not allow submitted application files or data to be replaced or changed after an application is submitted. This decision will help ensure no applicants receive an unfair advantage. Before submitting the application, please check it for completeness, accuracy, quality, and readability. This should include verifying that all graphic elements, including tables, charts, and images, converted properly when saving the original documents in PDF format as required.

2. Evaluation of Applications

The Department will use a multi-step evaluation process before making award determinations for all applications submitted in response to this FOA. The Department will consider the outcome of each of these evaluation steps in making final funding recommendations to the State Surgeon General.

A. Administrative Review

Application materials not received according to the date, time, and location specified in [Table 1](#). Schedule of Important Dates will be disqualified. Each application submitted by the deadline indicated in [Table 1](#) will receive an administrative review verifying mandatory eligibility requirements and the completeness of the application. The administrative review does not include review of the overall scientific impact.

Any application failing to meet all administrative requirements may be ruled ineligible for funding in response to this FOA and not entitled to further consideration and will not undergo peer review.

The Department reserves the right to disqualify all applications or to waive minor irregularities when doing so would be in the best interest of the State of Florida. A minor irregularity is defined as a variation from the specifications of this FOA that does not give any applicant an advantage or benefit not enjoyed by other applicants, does not affect the cost of the application, nor adversely affects the interests of the State. At its option, the Program may correct minor irregularities, but is under no obligation to do so.

B. Scientific Merit Peer Review

Department peer reviewers will assess the overall impact of all qualified/eligible applications. Peer review panels comprise reviewers with expertise in the substance and methodology of the proposed project. Individual reviewers will review and rate applications, including assessing cancer-relatedness, health impact, examining budget requests, and recommending the level of support necessary to complete the work. Reviewers will be nationally prominent individuals drawn from various sectors in the life sciences including universities, government agencies, and industry. Reviewers will be located outside of Florida and will not be associated with any

Florida-based public or private entity working in the life sciences. Before being granted access to proposals, every reviewer will be required to accept the terms of a Confidential Nondisclosure Agreement. Reviewers are required to disclose financial interests to the Department, and the Department determines if any disclosed financial interests are conflicts of interests. Reviewers with financial conflicts of interest are not allowed to review applications. Reviewers will receive honoraria for their participation and are expected to set a high standard for scientific excellence. The number and composition of peer review panels will be determined by the number and scientific range of applications received.

Overall Impact Score:

Like the National Institutes of Health, Board members will use a standard rating format:

- (1) Exceptional – Exceptionally strong with essentially no weaknesses
- (2) Outstanding – Extremely strong with negligible weaknesses
- (3) Excellent – Very strong with only some minor weaknesses
- (4) Very Good – Strong but with numerous minor weaknesses
- (5) Good – Strong but also at least one moderate weakness
- (6) Satisfactory – Some strengths and some moderate weaknesses
- (7) Fair – Some strengths but with at least one major weakness
- (8) Marginal – A few strengths and a few major weaknesses
- (9) Poor – Very few strengths and numerous major weaknesses

Scientific Merit Peer Reviewers will rate all proposals for overall impact on the following criteria:

- Significance: the importance of the topic being addressed.
- Investigators: the qualifications of the key personnel contributing to the project.
- Innovation: the potential for the project to shift current paradigms.
- Approach: the appropriateness of the planned strategy, methodology, and analyses.
- Environment: the suitability of institutional support, equipment, and physical resources.
- Health impact on the people of Florida.

C. Programmatic Review

The Department and the Board will consider the scientific merit peer review scores in a manner that eliminates or appropriately manages any conflicts of interest. Other programmatic interests, such as the availability of funds, and Program goals and preferences, will be used to form a funding recommendation to the State Surgeon General.

3. Notification of Funding Decision

The applicant organization and PI will receive written notification of the funding decisions as indicated in Table 1. Schedule of Important Dates. All awards in response to this FOA are subject to the availability of funds and spending authority provided by the Florida Legislature. By submitting a grant application pursuant to this Funding Opportunity, all applicants acknowledge and consent to this condition.

4. Requests for Re-Consideration

All funding decisions of the State Surgeon General are final.

5. Grantee Requirements

A. Terms and Conditions

After awards are made, each grantee must sign a contract, called the “Terms and Conditions,” agreeing to certain legal requirements of the award. The “Terms and Conditions” are non-negotiable and acceptance is required as part of the grant award process. The Department reserves the right to change or modify the “Terms and Conditions” as needed. The “Terms and Conditions” include the post-award schedule of deliverables.

B. Grantee Reporting Requirements

If the applicant’s proposal is funded, the Grantee must respond to Department requests for information for a period of five (5) years after the end of the grant period, including any no cost extensions. The requested information may include but is not limited to long-term outcomes based on the funded project, including the value of additional grant awards for AD research, a list of AD presentations, a list of AD publications in peer-reviewed journals, commercialization results and any invention disclosures, patent filings, and patents received. Open Innovation and Sharing of Publication-Related Materials, Data, and Software Publishing a scientific paper is a transaction whereby the author(s) receive credit and status in exchange for sharing their scientific findings. Authors have a responsibility to make available materials, databases, and software integral to their findings so that others may validate or refute the results and/or extend them in new directions. Grantees funded through the Department are encouraged to use material transfer agreements to make materials, data and databases, and software that result from this funding and which is integral to their research findings, freely and promptly available upon request for research use by other scientists.

In accord with the NIH notice NOT-OD-08-033, Grantees shall submit or have submitted for them to the National Library of Medicine’s PubMed Central an electronic version of their final, peer-reviewed manuscripts upon acceptance for publication, to be made publicly available no later than 12 months after the official date of publication, in a manner consistent with copyright law. This applies to all publications resulting from the Department funded projects/research. For more information on the NIH Open Access Policy visit <http://publicaccess.nih.gov/>. A copy of the electronic version of final, peer-reviewed, published manuscripts must be submitted to the Department when submitting the current quarterly progress report.

V. APPENDIX

1. Reportable Financial Interests

**Sample. Subject to revisions.

Florida Department of Health Financial Conflict of Interest in Research	
Principal Investigator: _____	
Title of project: _____	
Grant number: _____	
Step 1: Use the following tests to determine if the researcher and the researcher's immediate family, or any other personnel on the grant (sub-investigators and research staff) and their immediate families, have any of the following financial interests related to the research:	
"Immediate Family" means spouse, domestic partner, children, and dependents.	
"Financial Interest Related to the Research" means financial interest in the sponsor, product or service being tested, or competitor of the sponsor.	
<input type="checkbox"/> Ownership interest, stock options, or other financial interest of any value related to the research. Does not include mutual funds or companies publicly traded on a stock exchange.	
<input type="checkbox"/> Compensation of any value related to the research.	
<input type="checkbox"/> Proprietary interest related to the research of any value including, but not limited to, a patent, trademark, copyright or licensing agreement.	
<input type="checkbox"/> Board or executive relationship in a company (such as a startup company but including publicly traded companies) related to the research, regardless of compensation.	
<input type="checkbox"/> Any arrangement where the value of the ownership interests will be affected by the outcome of the research. For example, an arrangement has been made where the value of stock options given to the researcher by a startup company will vary depending on the outcome of the research.	
<input type="checkbox"/> Any other interest that could be affected by the outcome of the research	
If any of the following above conditions are met, provide a description of financial interests related to the research:	
<input type="checkbox"/> The grantee has no financial interests requiring disclosure	
Signed _____ Dated _____	
Failure to disclose financial interests related to the research, and failure to provide an updated disclosure at least at the time of the continuation request or if the financial interests of the researcher and personnel on the grant change, may result in:	
- Immediate termination of the grant.	
- Financial consequences, including repayment of all grant funds.	
- Any other action required by state law.	

2. Budget Guidance

1. General Instructions: Budget documents are in Excel format and available in the PeerNet application. When calculating the budget summary and narrative be sure to round each number to the whole dollar indicating there are not cents (\$0,000.00). The budget summary contains totals for each fiscal year and calculations for determining total grant costs. The budget summary must correspond to the calculations in the budget narrative.
2. The budget contains two parts, Attachment V Budget Summary and Budget Narrative:
 - a) The Budget Summary provides an overview of the estimated budget for the life of the grant by category and by State Fiscal Year (July 1 - June 30). Do not use calendar months to calculate the budget. The grant start date is anticipated to begin April 1, 2024 (FY 23-24 the first three months of the grant). The first fiscal year grant budget should be calculated for three months. Each remaining year will be for 12 months (July–June) The final budget year should be calculated for nine months.
 - b) The Budget Narrative provides information regarding how expenses will be used to support the grant. Each budget category requested should include enough detail to justify the expense.
 - i. Personnel/Fringe: A brief description of the staff member's role on the project, percent of effort and any other specific rates or cost breakdowns to justify the total personnel and fringe expense. Be sure to account for any cost-of-living increases and include a statement in the narrative. Cost of living increases are limited to 3 percent per year. Detailed calculations are required to justify the cost for each staff and each entry should be round to the whole dollar (Ex: Total Salary/Fringe \$ x %).
 - ii. Indirect Costs: Indirect cost rates may not exceed 15 percent of the total direct costs requested. Direct costs are all expense categories directly associated with the research project.



Attachment V Grant Budget Summary

Institution:		Principal Investigator:	
Grant Number:		Financial Contact:	

BUDGET CATEGORY	FISCAL YEAR ONE 2023-2024 BUDGET (4/1/24-6/30/24)	FISCAL YEAR TWO 2024-2025 BUDGET (7/1/24-6/30/25)	FISCAL YEAR THREE 2025-2026 BUDGET (7/1/25-6/30/26)	FISCAL YEAR FOUR 2026-2027 BUDGET (7/1/26-6/30/27)	FISCAL YEAR FIVE 2027-2028 BUDGET (7/1/27-6/30/28)	TOTAL BUDGET
Personnel/ Fringe Benefits	\$0	\$0	\$0	\$0	\$0	\$0
Subcontracting	\$0	\$0	\$0	\$0	\$0	\$0
Equipment	\$0	\$0	\$0	\$0	\$0	\$0
Supplies	\$0	\$0	\$0	\$0	\$0	\$0
Travel	\$0	\$0	\$0	\$0	\$0	\$0
Patient Care	\$0	\$0	\$0	\$0	\$0	\$0
Other Expenses	\$0	\$0	\$0	\$0	\$0	\$0
DIRECT COST SUB-TOTAL:	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Indirect Amount:	\$0	\$0	\$0	\$0	\$0	\$0
TOTAL:	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -

GRANTEE	FLORIDA DEPARTMENT OF HEALTH
Signature of Authorized Official	Signature of Authorized Official
Name:	Name:
Title:	Deputy Director, Public Health Research Biomedical Research Section
Date:	Date:

- INSTRUCTIONS:**
1. The budget must include the entire proposed project cost broken down by category and state fiscal year (July 1–June 30).
 2. Complete the appropriate number of columns below as appropriate for the term of your grant award.
 3. The total budget may not exceed the award amount and should be rounded to the nearest **whole dollar amount**.
 4. Cost of Living Adjustments are allowable on Fiscal Year Two and forward, not to exceed 3%. Please note, a standard statement has been included on the Budget Narrative.
 5. Contractual Costs requires additional forms and prior approval, including a copy of the draft/proposed subcontract.
 6. Budget categories may not be altered, combined, or revised.
 7. Modified Total Direct Cost (MTDC): Hard enter the total for each fiscal year. Formulas will calculate the indirect cost rate x the MTDC amount, not to exceed 15%. Excluded costs should be clearly identified on the Budget Narrative.
 8. Indirect costs are limited to no more than 15% of the modified total direct costs requested.
 9. Where appropriate, include details that show how the estimated cost was calculated.
 10. If changes are needed to adjust direct costs throughout the life of the grant, a budget change request must be submitted and approved.
 11. Insert additional rows in the Personnel chart as necessary. The remaining budget category text boxes will expand as you type. Select ALT + Enter to go to the next line.
 12. Please contact your assigned Grant Manager for assistance.

FDOH Rev. 5/1/2023

Biomedical Research Grant Budget Narrative							
FISCAL YEAR ONE 2023-2024 (3 Month Budget April - June)							
Personnel/Fringe							
Name/Role on Project	Annual Base Salary	% Effort on Project	Project Salary Total (Salary/12 months x 3 months x % Effort)	Fringe %	Fringe Amount (Column D x E)	Fringe Fixed/Flat Rate (if applicable)	Total Personnel & Fringe (Column D + F + G)
	\$0	0.00%	\$0	0.00%	\$0	\$0	\$0
			\$0		\$0		\$0
			\$0		\$0		\$0
			\$0		\$0		\$0
			\$0		\$0		\$0
TOTAL PERSONNEL COST:							\$0
Subcontracting (Contractual Services require pre-approval by DOH)							
							\$0
Equipment (Itemize all equipment costs and include how the equipment will be used toward the research project. Show total cost of category)							
							\$0
Supplies (This line item may be adjusted to bring the budget to the exact award amount)							
							\$0
Travel (Domestic travel will be reimbursed in accordance with s.112.061, Florida Statutes. Lodging costs may not exceed \$175 per night)							
							\$0
Patient Care Costs (Itemize estimated patient care costs)							
							\$0
Other Expenses (Itemize all Other expense costs)							
							\$0
Indirect (Show Total Direct Costs x Rate % = \$Total Indirect Costs)							
							\$0

Biomedical Research Grant Budget Narrative							
FISCAL YEAR TWO 2024-2025 (12 Month Budget)							
Personnel/Fringe							
Name/Role on Project	Annual Base Salary	% Effort on Project	Project Salary Total (Salary x % Effort)	Fringe %	Fringe Amount (Column D x E)	Fringe Fixed/Flat Rate (if applicable)	Total Personnel & Fringe (Column D + F + G)
	\$0	0.00%	\$0	0.00%	\$0		\$0
			\$0		\$0		\$0
			\$0		\$0		\$0
			\$0		\$0		\$0
			\$0		\$0		\$0
TOTAL PERSONNEL COST:							\$0
Subcontracting (Contractual Services require pre-approval by DOH)							
							\$0
Equipment (Itemize all equipment costs and include how the equipment will be used toward the research project. Show total cost of category)							
							\$0
Supplies (This line item may be adjusted to bring the budget to the exact award amount)							
							\$0
Travel (Domestic travel will be reimbursed in accordance with s.112.061, Florida Statutes. Lodging costs may not exceed \$175 per night)							
							\$0
Patient Care Costs (Itemize estimated patient care costs)							
							\$0
Other Expenses (Itemize all Other expense costs)							
							\$0
Indirect (Show Total Direct Costs x Rate % = \$Total Indirect Costs)							
							\$0

Biomedical Research Grant Budget Narrative							
FISCAL YEAR THREE 2025-2026 (12 Month Budget)							
Personnel/Fringe							
Name/Role on Project	Annual Base Salary	% Effort on Project	Project Salary Total (Salary x % Effort)	Fringe %	Fringe Amount (Column D x E)	Fringe Fixed/Flat Rate (if applicable)	Total Personnel & Fringe (Column D + F + G)
	\$0	0.00%	\$0	0.00%	\$0	\$0	\$0
			\$0		\$0		\$0
			\$0		\$0		\$0
			\$0		\$0		\$0
			\$0		\$0		\$0
TOTAL PERSONNEL COST:							\$0
Subcontracting <i>(Contractual Services require pre-approval by DOH)</i>							\$0
Equipment <i>(Itemize all equipment costs and include how the equipment will be used toward the research project. Show total cost of category)</i>							\$0
Supplies <i>(This line item may be adjusted to bring the budget to the exact award amount)</i>							\$0
Travel <i>(Domestic travel will be reimbursed in accordance with s.112.061, Florida Statutes. Lodging costs may not exceed \$175 per night)</i>							\$0
Patient Care Costs <i>(Itemize estimated patient care costs)</i>							\$0
Other Expenses <i>(Itemize all Other expense costs)</i>							\$0
Indirect <i>(Show Total Direct Costs x Rate % = \$Total Indirect Costs)</i>							\$0

FOOH Rev. 5/1/2023

Biomedical Research Grant Budget Narrative							
FISCAL YEAR FOUR 2026-2027 (12 Month Budget)							
Personnel/Fringe							
Name/Role on Project	Annual Base Salary	% Effort on Project	Project Salary Total (Salary x % Effort)	Fringe %	Fringe Amount (Column D x E)	Fringe Fixed/Flat Rate (if applicable)	Total Personnel & Fringe (Column D + F + G)
	\$0	0.00%	\$0	0.00%	\$0	\$0	\$0
			\$0		\$0		\$0
			\$0		\$0		\$0
			\$0		\$0		\$0
			\$0		\$0		\$0
TOTAL PERSONNEL COST:							\$0
Subcontracting <i>(Contractual Services require pre-approval by DOH)</i>							\$0
Equipment <i>(Itemize all equipment costs and include how the equipment will be used toward the research project. Show total cost of category,</i>							\$0
Supplies <i>(This line item may be adjusted to bring the budget to the exact award amount)</i>							\$0
Travel <i>(Domestic travel will be reimbursed in accordance with s.112.061, Florida Statutes. Lodging costs may not exceed \$175 per night)</i>							\$0
Patient Care Costs <i>(Itemize estimated patient care costs)</i>							\$0
Other Expenses <i>(Itemize all Other expense costs)</i>							\$0
Indirect <i>(Show Total Direct Costs x Rate % = \$Total Indirect Costs)</i>							\$0

FD0H Rev. 5/1/2023

Biomedical Research Grant Budget Narrative							
FISCAL YEAR FIVE 2027-2028 (9 Month Budget)							
Personnel/Fringe							
Name/Role on Project	Annual Base Salary	% Effort on Project	Project Salary Total (Salary/12 months x 9 months x % Effort)	Fringe %	Fringe Amount (Column D x E)	Fringe Fixed/Flat Rate (if applicable)	Total Personnel & Fringe (Column D + F + G)
	\$0	0.00%	\$0	0.00%	\$0	\$0	\$0
			\$0		\$0		\$0
			\$0		\$0		\$0
			\$0		\$0		\$0
			\$0		\$0		\$0
TOTAL PERSONNEL COST:							\$0
Subcontracting (Contractual Services require pre-approval by DOH)							
							\$0
Equipment (Itemize all equipment costs and include how the equipment will be used toward the research project. Show total cost of category)							
							\$0
Supplies (This line item may be adjusted to bring the budget to the exact award amount)							
							\$0
Travel (Domestic travel will be reimbursed in accordance with s.112.061, Florida Statutes. Lodging costs may not exceed \$175 per night)							
							\$0
Patient Care Costs (Itemize estimated patient care costs)							
							\$0
Indirect (Show Total Direct Costs x Rate % = \$Total Indirect Costs)							
							\$0

2. Terms and Conditions Template



Florida Department of Health, Grant Agreement for the Ed and Ethel Moore Alzheimer's Disease Research Grant Program

The Florida Department of Health (Department) requires that a Grant recipient, including its authorized agents, (Grantee) for the Ed and Ethel Moore Alzheimer's Disease Research Grant Program, comply with the following:

The Funding Opportunity Announcement (FOA), including any amendments, the grant application submitted by the Grantee in response thereto (Application), and the following Grant Terms and Conditions, are hereby incorporated by reference, and made a part of this Agreement:

GRANT TERMS AND CONDITIONS

1. **Compliance with Laws:** Grantee must comply with the provisions outlined in those documents, all applicable federal and State of Florida laws, rules, and regulations.
2. **Grant Period and Award:** The grant titled, «*Title*», total award amount, a description of the project funded by this grant, and other specific information about this grant are shown in Attachment I, Grant Information. The grant period will include the original term of the grant and all approved extensions. Awards, extensions, and payments will be made contingent upon satisfactory project performance and compliance with this Agreement. **The Department's performance and obligation to pay under this Agreement are contingent upon annual appropriation by the Florida Legislature and the availability of funds.**
3. **Starting the Grant Project:** This project may only begin with: executed Terms and Conditions; a Department approved budget; a conflict of interest form signed by the Principal Investigator (PI) and the following documents completed and submitted to the Department, as applicable: an approved management plan; an Institutional Review Board (IRB) approval(s); an Institutional Animal Care and Use Committee (IACUC) approval(s); an Institutional Biosafety Committee (IBC) approval(s); and a Radiation Safety Review(s). Grantee agrees to the following:
 - a. **Starting the Grant Project:** A five percent reduction will be assessed on that invoice, or the grant terminated, at the Department's sole discretion, if the grant project has not started within three months after the Agreement execution date.
 - b. **Institutional Authorization(s):** If the grant project requires the use of human subjects or vertebrate animals, recombinant DNA, stem cells, or radiation; the Grantee must submit to the Department the approval(s), and any applicable protocol(s) and consent form(s), within 10 days from execution of this Agreement, for all institutional authorizations including, but not limited to, an IRB, an IACUC, and an IBC approval, and a Radiation Safety Review. Any institutional authorization must include the grant title exactly as it appears in Section 2. Grant Period and Awards, of this Agreement. For additional details, review Section 26 below regarding the use of human subjects, Section 27 below regarding use of vertebrate animals, Section 28 below regarding recombinant nucleic acid, Section 29 below regarding stem cells, and Section 30 below regarding radiation safety reviews.

Any changes or modifications to institutional authorizations, protocols, or consent forms must be submitted to the Department no later than 10 working days after the approved change or modification. Failure to provide the Department of any approvals or changes to IRB, IACUC, or IBC approvals, or a Radiation Safety Review, will result in a 10 percent financial consequence being assessed on that invoice.

- c. **Monthly Updates:** Grantee must update the Department via email each month regarding the status of all applicable regulatory applications prior to receiving institutional authorization. Failure to update the Department as specified will result in a financial consequence of 10 percent being assessed on that invoice. Once all applicable institutional authorizations are received, and the Department has been sent a final update stating that all applications have been approved, the Grantee will no longer need to provide the Department with monthly updates.
- d. **Pending Institutional Authorizations:** The Grantee must request, in writing, from the Department's Grant Manager, authority to begin a portion of the grant project that does not deal with human subjects, vertebrate animals, recombinant DNA, stem cells, or radiation pending institutional authorization(s).
- e. **Grant Administration Manual:** For Grantees, an important reference document is the Grant Administration Manual, which contains Department policies as well as the procedures necessary for compliance with those policies. It is organized around a typical grant lifecycle. The Grant Administration Manual can be found on the Department's website in the Grant Management Forms Library and Other Resources at: <http://www.floridahealth.gov/provider-and-partner-resources/research/grant-programs-resources/forms-library.html>.

4. Scope of Work and Project Adjustments:

- a. Grantee must complete all work as described in the approved application.
- b. Any changes or adjustments in the designs, aims, or research plans as proposed in the application; any changes requiring IRB, IACUC, or IBC approvals, or Radiation Safety Review; and any change that may result in a conflict of interest, must be submitted in writing and are subject to Department approval prior to the change taking place. Failure to obtain prior written approval from the Department will result in either a 20 percent financial consequence being assessed on that invoice or termination of the grant, at the Department's sole discretion.

5. Required Documentation: Grantee must provide reports to the Department describing the impact of the research on health outcomes; scientific impact such as publications in peer-review journals, presentations, collaborations, or patents; and any subsequent additional grant funding related to the research subject. Failure to comply with the following requirements will result in either a 10 percent financial consequence being assessed on that invoice or grant termination, at the Department's sole discretion:

- a. Grantee must prepare quarterly financial reports and narrative progress reports, which include a description of the impact of the research on health outcomes and other deliverables as outlined in Attachment II. Reports must be submitted to the Department within one month of the end of each quarter and received no later than close of business 5: 00 p.m., E.S.T. on the dates outlined in Attachment II. Reports must be prepared in the

format specified by the Department. Failure to use the correct report templates will result in delay of payment. Quarterly report templates are provided on the Department's website located at: <http://www.floridahealth.gov/provider-and-partner-resources/research/grant-programs-resources/forms-library.html>.

- b. Grantee must prepare annual and final Florida Legislative Progress Reports to be used in the preparation of the statutorily required annual report to the Florida Legislature and Governor. Grantee will make all reasonable efforts to assist the Department in gathering data required for reporting to the Florida Legislature and Governor pursuant to section 381.922(6) or 215.5602(10), Florida Statutes, and other laws, as applicable, both during and after the grant period. Upon request, Grantee agrees to report to the Department a description of all outcomes resulting from this grant, including but not limited to a description of the impact of the research on health outcomes, publications, presentations, peer-reviewed journal articles, databases, additional grants and monies received, postsecondary educational institutional involvement, patents, inventions disclosures, collaborations, and copyrights. The narrative report is intended for a general audience and should be limited to 500 words. The report is due annually by October 31. The report template is provided on the Department's website located at: <http://www.floridahealth.gov/provider-and-partner-resources/research/grant-programs-resources/forms-library.html>.
6. **Grant Project Deliverables:** Failure to provide the deliverables specified in Attachment II, Schedule of Deliverables and Payments, will result in a financial consequence of 10 percent being assessed on that invoice or grant termination, at the Department's sole discretion.
7. **Fiscal Quarters:** There are four quarters in the State fiscal year, consisting of three months each. The quarters are as follows: Quarter 1 is July 1 through September 30; Quarter 2 is October 1 through December 31; Quarter 3 is January 1 through March 31; and Quarter 4 is April 1 through June 30.
8. **Payment:** This grant has a fixed payment schedule as shown in Attachment II. Payments will be contingent on Grantee complying with this Agreement and the following:

 - a. Grantee must request payment using the Department's invoice form, located at <http://www.floridahealth.gov/provider-and-partner-resources/research/grant-programs-resources/forms-library.html>. Only allowable expenditures will be reimbursed by the Department. If the Department or the Department of Financial Services (DFS) requires additional information regarding reported expenditures, the Grantee must provide the requested information no later than three working days from the time of notification from the Department's Grant Manager. Failure to provide additional requested information within three working days will result in a 10 percent financial consequence being assessed on that invoice.
 - b. Grantee will only be paid for satisfactory and timely completion of the deliverables. Payment of the final invoice for a grant will take place after the end of the grant period and all required deliverables have been received and approved by the Department. A final reconciliation of expenditures during the life of the grant will impact the final invoice. The final payment will total all reconciled grant expenditures.
 - c. Total payment received under this Agreement cannot exceed the total award amount.

- 9. Key Personnel Requirements and Adjustments:** Project key personnel include the Corresponding PI, Co-PI(s), Project Director, Mentor, and other project personnel noted as such in the grant application.
- a. Commitment of any individual's effort greater than 100 percent, including all Department Biomedical Research grants, is not permitted.
 - b. Grantee must establish a system to track work effort commitments of all key personnel. Effort certification documentation must indicate the committed or actual work effort expended on the grant during the grant period as well as the percentage of effort performed for all deliverables. All effort assigned to this grant must be for work directly related to the project.
 - c. Prior Department approval is required for Project Director, Corresponding Principal Investigator, Co-PI(s), and Mentor changes. The Grantee must complete and submit to Department via email the Key Personnel Change/Change in Effort form for any changes to Project Director, Corresponding PI, Co-PI(s), and Mentor. This form can be found at: <http://www.floridahealth.gov/provider-and-partner-resources/research/grant-programs-resources/forms-library.html>. Changes to any of these roles without the prior written approval of the Department will result in a 10 percent financial consequence being assessed on that invoice or grant termination, at the Department's sole discretion.
 - d. Replacement of or reduction in the effort of the Project Director or Co-PI(s) are not allowed within the first year and may not be decreased more than 10 percent within any one year of the grant period. The amount of effort of the Project Director or Co-PI(s) must remain consistent with the approved budget and any approved changes.
- 10. Budget:** The current approved budget is the Attachment V, approved by the Department at the beginning of the grant and includes any approved budget changes.
- a. The Department will reimburse Grantee for allowable, reasonable, and necessary costs as detailed in Attachment V.
 - b. Budget changes may be made anytime during the life of the grant. Overspending in any category must be justified and approved by the Department prior to making such expenditure. The Grantee must complete the Budget Change Request form and submit it to the Department's Grant Manager via email. The Budget Change Request form can be found at <http://www.floridahealth.gov/provider-and-partner-resources/research/grant-programs-resources/forms-library.html>. Approved revisions to the grant budget will become effective upon approval by the Department.
 - c. The Department reserves the right to: 1) require further justification, 2) reject any disallowed costs, and 3) request new or revised budgets, as it deems necessary.
- 11. No-Cost Extension:** Requests for No-Cost Extension must meet the following requirements:
- a. Grantee must submit the Department's Request for No-Cost Extension form, including the completed Cumulative Grant Progress Report, to the Department's Grant Manager no later than three months prior to the end date of the grant specified in Attachment II. Any no-cost extension request received after the three-month deadline will not be considered by the Department for approval.

- b. Grantee will not be eligible for more than one, six-month, no-cost extension. Grants awarded for 54 months are not eligible for a no-cost extension.
- c. No additional grant funding will be provided to the Grantee if the no-cost extension request is approved by the Department.

12. Property and Equipment: Property and equipment is defined as non-expendable, tangible property having a useful life of more than one year with a cost of \$5,000 or more. All property and equipment purchased with grant funds must be 1) necessary to carry out the proposed research; 2) justified to and pre-approved by the Department; 3) inventoried and tracked throughout the grant period; and 4) protected with sufficient insurance and security safeguards. Grantee must ensure the following:

- a. All approved property and equipment must be purchased and received prior to the last three months of the grant period unless prior written approval from the Department has been obtained.
- b. All equipment purchased with grant funds is the property of the eligible institution, and is subject to Chapter 273, Florida Statutes, dealing with state-owned tangible personal property and the disposition thereof. For research institutions not covered under Chapter 1000, Florida Statutes, equipment no longer deemed to be useful will remain state property and must be transferred or donated to a state agency or public university for redistribution or disposition.

13. Fiscal Accountability: Grantee must establish and maintain books, records, and documents (including electronic storage media) in accordance with generally accepted accounting procedures and practices, which sufficiently and properly reflect all revenues and expenditures of funds provided by the Department.

- a. Grantee must not commingle grant funds with other personal or business accounts. Grantee must not use grant funds to supplant or replace funds from other resources.
- b. Grantee must maintain sufficient documentation of all grant expenditures as proof that such expenditures are allowable, reasonable, and necessary for the work performed under this agreement. Grantee may not charge the Department for the value of donated goods, services, or facilities.
- c. Grantee must develop and use a system for tracking all project costs incurred. All expenses paid with grant funds must be directly related to the project. Any grant funds utilized for purposes outside of the approved budget will be considered an overpayment and must be returned to the Department.
- d. The Department will not be responsible for any project costs incurred before or after the grant period. Only project costs incurred during the grant period are eligible for payment. All project costs are subject to Department audit, and only those required for this project during the grant period, will be allowed.
- e. Per section 112.061, Florida Statutes, reimbursement for allowed travel must be at or below the current State of Florida travel rates. To implement appropriations in the General Appropriations Act for State travel and notwithstanding section 112.061, Florida Statutes, costs for lodging associated with a meeting, conference, or convention organized or

sponsored in whole or in part by a state agency or the judicial branch may not exceed the current State of Florida conference travel rates. For all other travel, the lodging travel rate is \$175.00. The Grantee will not be reimbursed for reservations made through third party travel sites (e.g., Booking.com, Expedia, Orbitz). Grantees must submit a travel voucher form in every quarter in which they charged travel to their grant budgets. Travel is only approved within the United States, including its territories. The State of Florida Voucher for Reimbursement of Travel Expenses should be used for all travel-related expenses unless the Grantee's institutional travel voucher or expenditure form has received prior approval from the Department of Financial Services. Support documentation for all travel-related expenses is needed, e.g., receipts for flight, hotel, parking, rental car, fuel, ground transportation, as well as registration, meeting agenda or schedule, and copy of any presentation made. Do not use acronyms or abbreviations on travel forms or documentation. The State of Florida Voucher for Reimbursement of Travel Expenses may be found at: <http://www.floridahealth.gov/provider-and-partner-resources/research/grant-programs-resources/forms-library.html>.

- 14. Return of Funds:** The final invoice is based on a reconciliation of all costs associated with the project, not to exceed the fixed amount indicated in Attachment II. The Grantee must return to the Department any overpayment of grant funds related to disallowed expenditures, funds unaccounted for due to non-submission of required deliverables, or other unused grant funds at the end of the grant period. If the Grantee or its independent auditor identifies that overpayment has been made; the Grantee must repay the overpayment within three months of grant end date. In the event the Department first discovers an overpayment has been made, the Department will notify the Grantee of such a finding. Should repayment not be made in a timely manner, the Department may withhold the amount of the overpayment from any future payments under this or any other agreement. This provision will not be a limitation on any remedies at law or equity available to the Department.
- 15. Monitoring:** The Grantee must permit persons duly authorized by the Department to inspect any records, papers, documents, facilities, or goods and services of the Grantee that are relevant to this grant, and interview any clients, subcontractors, and employees of the Grantee to assure the Department of satisfactory performance of the Terms and Conditions of this grant. Monitoring may take place at any time during the grant period or records retention period, with reasonable advance notice, during normal business hours. Following such evaluation, the Department may deliver to Grantee a written report of its findings and may include written recommendations about Grantee's performance of the Terms and Conditions of this grant. Grantee will correct all noted deficiencies identified by the Department within the specified period set forth in the recommendations. Grantee's failure to correct noted deficiencies may, at the sole and exclusive discretion of the Department, result in any one or a combination of the following: 1) Grantee being deemed in breach or default of this agreement; 2) the withholding of payments to Grantee by the Department under this or any other agreement; 3) the termination of this grant.
- 16. Access to Records:** All records related to this grant will be subject at all reasonable times to inspection, review, or audit by federal, state, or personnel duly authorized by the Department. Persons duly authorized by the Department will have full access to and the right to examine any of the Grantee's grant and related records and documents, regardless of the form in which kept, at all reasonable times for as long as records are retained. Upon termination of the grant, and at the request of the Department, the Grantee will cooperate with the Department to facilitate the duplication and transfer of any said records or documents during the required retention period. The Department unilaterally reserves the right to terminate this grant if the

Grantee refuses to allow public access to all documents, papers, letters, or other materials subject to provision of Chapter 119, Florida Statutes, made or received by the Grantee or its contractor in conjunction with this grant.

- 17. Retention of Records:** The Grantee must retain all client records, financial records, supporting documents, statistical records, and any other documents (including electronic storage media) pertinent to this grant for a period of six years after the end of the grant period. If an audit has been initiated and audit findings have not been resolved at the end of the six years, the records must be retained until resolution of the audit findings or litigation, which may be based on the terms of this grant. Upon completion or termination of the grant and at the request of the Department, Grantee will cooperate with the Department to facilitate the duplication and transfer of any said records or documents during the required retention period as specified.
- 18. Public Records:** The Grantee must keep and maintain public records, as defined in Chapter 119, Florida Statutes that are required by the Department to perform the services required by the grant. Upon request from the Department's custodian of public records, provide the Department with a copy of the requested public records or allow the records to be inspected or copied within a reasonable time at a cost that does not exceed that provided in Chapter 119, Florida Statutes, or as otherwise provided by law. Ensure that public records that are exempt or that are confidential and exempt from public record disclosure are not disclosed, except as authorized by law for the duration of the grant term and following completion of the grant if Grantee does not transfer the public records to the Department. Upon completion of the grant, transfer to the Department at no cost, all public records in possession of Grantee or keep and maintain public records required by the Department to perform the grant services. If Grantee transfers all public records to the Department upon completion of the grant, Grantee will destroy any duplicate public records that are exempt or confidential and exempt. If Grantee keeps and maintains public records upon completion of the grant, Grantee will meet all applicable requirements for retaining public records. All records stored electronically must be provided to the Department, upon request of the Department's custodian of public records, in a format that is compatible with the information technology systems of the Department. The Department may unilaterally terminate this grant if Grantee refuses to allow access to all public records made or maintained by Grantee in conjunction with this grant, unless the records are exempt from section 24(a) of Art. I of the State Constitution and section [119.07\(1\)](#), Florida Statutes.

If the Grantee has questions regarding the application of Chapter 119, Florida Statutes, to the Grantee's duty to provide public records relating to this Agreement, contact the custodian of public records at 850-245-4005, PublicRecordsRequest@flhealth.gov or 4052 Bald Cypress Way, Bin A02, Tallahassee, FL 32399.

19. Financial Overlap: Other Support is defined as all financial resources, whether federal, state or private, commercial or institutional, available in direct support of an individual's research endeavors, including but not limited to research grants, cooperative agreements, contracts, and institutional awards (not included are training awards, prizes, or gifts). Financial overlap is defined as accepting financial compensation from one or more other support sources for the same or substantially similar scientific aims/projects that are funded by the Department. Financial overlap is not permitted. Grantee is responsible for monitoring changes in other support for project key personnel to avoid financial overlap. Grantee is responsible for notifying the Department of such changes and for resolving overlap or requesting an amendment to prevent overlap. If financial overlap is due to receipt of an award from another funding source during the grant period, Grantee must notify the Department within 48 hours and resolve the overlap by: a) modifying the start date or project aims of the new award to eliminate the overlap or b) relinquishing one of the awards. Updated information on other support may be requested by and must be provided to the Department at any time during the grant period. Failure to notify the Department within 48 hours will result in a financial consequence of 20 percent on the invoice.

20. Financial Conflict of Interest: The Grantee must report to the Department any reportable interests, regardless of any conflict-of-interest procedures at Grantee's institution, at the time of the application and before the grant starts. Grantee must have in place an administrative process to identify and resolve financial conflicts of interest that may affect the objectivity of the proposed research. Grantee must inform the Department of any conflict-of-interest management plan required by Grantee's institution prior to starting research. The Department may require an additional management plan if the plan developed by Grantee's institution is not acceptable to the Department. If a reportable interest as defined by the Department arises after the grant starts, Grantee must notify the Department within 48 hours. Failure to notify the Department within 48 hours will result in a financial consequence of 10 percent on the invoice.

21. Assignment, Subcontracts, and Sub-grants: The Grantee must neither assign any responsibility of this grant to another party nor subcontract for any of the work contemplated under this grant without prior written approval of the Department. Any sub-license, assignment, subcontract, or transfer otherwise occurring must be null and void. No subcontracts, or sub-grants will be authorized that involve researchers outside of the State of Florida. However, the Department may make exceptions, if the service is essential and only provided outside the state, and if the subcontract or sub-grant amount is less than 10 percent of the grant award amount. Grantee will be responsible for all work performed and all expenses incurred for this grant and for ensuring compliance with these Terms and Conditions. If the Department permits Grantee to subcontract part of the work contemplated under this grant, including entering in to subcontracts with vendors for services and commodities, it is understood by Grantee that the Department will not be liable to the subcontractor for any expenses or liabilities incurred under the subcontract and Grantee will be solely liable to the subcontractor for all expenses and liabilities incurred under the subcontract. To the extent permitted by Florida Statutes, Grantee, at its expense, will defend

the Department against such claims. The Department must be entitled to assign or transfer, in whole or in part, its rights, duties, or obligations under this agreement to another governmental agency in the State of Florida upon giving prior written notice to Grantee.

22. Confidentiality: The Grantee must maintain confidentiality of all data, files, documents, papers, electronic storage media, and records, including client records, and must protect the privacy of human subjects related to this grant and all services provided. Grantee must not use or disclose any information concerning human subjects under this grant for any purpose not in conformity with applicable state and federal law or regulations (including but not limited to 45 CFR 46, 45 CFR 160, 162, and 164, 21 CFR 45, and 21 CFR 56.111) and Department Institutional Review Board policies, except upon written consent of the recipient, or his or her responsible parent or guardian, when authorized by law. Grantee must report any breach of confidentiality to the Department within 48 hours of an allegation being made. Failure to report any breach of confidentiality to the Department within 48 hours will result in a financial consequence of 10 percent on the invoice.

23. Publications, Presentations, Patents, or Printing of Reports: Any publications, presentations, patents, printed reports, materials designed for use by the general public (e.g., educational pamphlets), or resulting research findings related to this grant must acknowledge the appropriate funding source: Florida Department of Health, Public Health Research, Biomedical Research Program. Grantee must notify the Department of all publications, presentations, patents, printed reports, materials designed for use by the general public, and research findings as a result of this grant both during the grant period and for a period of six years after the grant ends. Return on Investment surveys will be sent to prior grantees for completion which measures the long-term impact of the research grant funds. The Grantee is to provide the Department a copy of each peer-reviewed journal article that is published. Further, if research is presented at a conference, the presentation, poster, and abstract should be submitted to the Department. If the presentation was scientific, a summary should be developed and submitted that can be understood by and provided to the general public.

24. Public Access: The following provisions ensure public access to materials resulting from this grant:

- a. Upon publication of their work, grantees funded through this Program are encouraged to make materials, data and databases, and software that result from this funding and which is integral to their publication, freely and expeditiously available upon request for research use by other scientists, utilizing material transfer agreements.
- b. In concert with the NIH notice NOT-OD-08-033, Grantee must submit or have submitted for them to the United States' National Library of Medicine's PubMed Central, an electronic version of their final, peer-reviewed manuscripts upon acceptance of the publication, to be made publicly available no later than 12 months after the official date of publication, in a manner consistent with copyright law.

25. Patents, Copyrights, Trademarks, and Royalties: The following provisions will apply to all inventions, including intellectual property created by this grant:

- a. All inventions will be the property of Grantee or business partner if a written agreement has been executed; and Grantee will retain the entire right, title, and interest to such.

- b. Grantee will grant the State of Florida a fully paid up, non-exclusive, non-transferable, irrevocable license to practice or have practiced or to use or have used the invention for or on behalf of the State of Florida.
- c. Grantee must disclose all inventions to the Department in the applicable quarterly report of patent application or any licensing event and will subsequently report on commercialization progress regarding patenting (filing dates and issue dates), licensing, and commercialization events. Noncompliance will result in a financial consequence of 10 percent on the invoice.
- d. Grantee will make reasonable efforts to commercialize such invention through patenting and licensing and will make reasonable efforts to give preference to Florida-based companies.
- e. If Grantee seeks to apply for copyright, trademark, or patent when commercially reasonable for any property created, developed, or invented as a result of services provided under this grant, Grantee must furnish the Department with a description of said property and a copy of any licensing obtained.
- f. During the grant period the Grantee must report to the Department, any progress in securing or exploiting such inventions, trademarks, copyrights, or patents, and for a period of six years after the grant ends.
- g. It is expressly agreed that neither Grantee nor Department transfers, by operation of this agreement, to the other party any right in or license to any patents, copyrights, or other proprietary right owned as of the commencement date of the agreement or arising outside of the research conducted under this agreement.

26. Policy Regarding Scientific Misconduct: The following provisions must apply to ensure research integrity and manage scientific misconduct:

- a. Applicants for, and recipients of, grants must promptly inform the Department of any notices of scientific misconduct or suspensions. If an administrative action for scientific misconduct is imposed by the Department of Health and Human Services (HHS), by his/her own institution, or by any other regulatory agency, Grantee must notify the Department within 48 hours. Grantee must provide a copy of the final notice of the administrative action (i.e., after the disposition of any appeal) to the Department either at the time of application or within 1-month of the imposition of the administrative action. Noncompliance will result in a financial consequence of 20 percent on the invoice or grant termination.
- b. Each eligible institution that receives or applies for a grant must certify establishment of administrative policies consistent with 42 CFR 50, Subpart A, "*Responsibility of PHS Awardee and Applicant Institutions for Dealing with and Reporting Possible Misconduct in Science*," and 42 CFR 94, "*Public Health Service Standards for the Protection of Research Misconduct Whistleblowers*."

27. Human Subjects: The following provisions must apply if the project involves human subjects:

- a. Grantee must comply with all applicable federal and state laws and regulations, including 45 CFR 46, 45 CFR 160 and 164, and 21 CFR 50, 56, 312, 812, and other applicable

regulations, when research is covered by regulations, or the organization has committed to applying federal regulations or equivalent protections to all research.

- b. Grantee must obtain, maintain, and provide to the Department an active IRB approval letter before project work can begin. The approval letter must include Corresponding Principal Investigator's name, grant title exactly as it appears in these Terms and Conditions, approval date, expiration date, and the signature of the approving authority chairperson.
- c. Grantee is responsible for safeguarding the rights and welfare of human subjects in Department-supported projects. Grantees proposing to involve human subjects in nonexempt research must provide, upon request, a copy of the organization's Assurance of Compliance with the Office of Human Research Protections (OHRP) and must establish and maintain appropriate policies and procedures for the protection of human subjects.
- d. Grantees are required to obtain and maintain approval from an IRB accredited by the AAHRPP, or an IRB acceptable to the Department, within two months of notice of award. Grantees are required to follow Department policies for reporting unanticipated problems and non-compliance involving the research to the Department.
- e. When appropriate, Grantee agrees to define the arrangements for medical care for research-related injury before the research starts and communicate it to prospective research subjects. This does not require any party to be responsible for such care; it requires that it be made clear to subjects through the informed consent document/process who will provide medical care and who will be responsible to pay for it, should a subject experience a research-related injury.
- f. Grantee agrees to report to the Department within 48 hours, any expiration of IRB approval, serious or continuing non-compliance, unanticipated problems involving risks to subjects or others, and any suspension or termination of IRB approval. Grantee's IRB must report to the Department when reporting to federal officials any serious or continuing non-compliance or unanticipated problem involving risks to subjects or others. Noncompliance will result in a financial consequence of 10 percent on the invoice or grant termination.
- g. During the time that one or more IRB approval(s) is expired, all activities covered by the expired IRB approval(s) must stop until approval is obtained, and expenses for those activities during the expired period will be disallowed.
- h. Grantee must comply with NOT-OD-18-014: "*NIH Policy and Guidelines on the Inclusion of Women and Minorities as Subjects in Clinical Research.*"
- i. Research subjects can receive participation payments. Grantees must provide the page of the approved IRB protocol that indicates the research participant payment form and amount. Participant payment distribution logs with all personal information redacted will be required with each invoice. The logs will serve as an accounting of incentives given to research subjects each quarter. A summary of the log must be included with each invoice that provides the total number of participant visits for the quarter, the unit cost for participant payments, visit type, and the total cost for participant payments for each quarter. An example of this required documentation can be found at: [http:](http://)

[//www.floridahealth.gov/provider-and-partner-resources/research/grant-programs-resources/forms-library.html](http://www.floridahealth.gov/provider-and-partner-resources/research/grant-programs-resources/forms-library.html).

- 28. Vertebrate Animals:** If this project involves the use of vertebrate animals, the following terms apply:
- a. Grantee is responsible for the humane care and use of animals in Department-supported research activities. Grantee must abide by the Animal Welfare Act as amended (7 USC, 2131-2159) and other Federal statutes and regulations relating to animals.
 - b. Grantee must obtain, maintain, and provide to the Department active verification or certification of Institutional Animal Care and Use Committee (IACUC) approval before project work can begin. The verification must include Corresponding Principal Investigator name, the exact grant title, approval and expiration dates, and signature of the approving authority chairperson.
 - c. Grantee must report within 48 hours to the Department, any expiration of IACUC approval, serious or continuing non-compliance, and any suspension or termination of IACUC approval. Noncompliance will result in a financial consequence of 10 percent on the invoice.
 - d. During the time that the IACUC approval is expired, all activities covered by the expired IACUC approval must discontinue until a renewal is obtained, and expenses for those activities during the expired period will be disallowed.
- 29. Recombinant Nucleic Acid:** All research involving Recombinant Nucleic Acid techniques must meet the requirements of the *“NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules.”* The Corresponding Principal Investigator is responsible for verifying if IBC approval is warranted.
- 30. Stem Cells:** All research involving human stem cells must meet the requirements of the *“National Institutes of Health Guidelines for Human Stem Cell Research.”* The Corresponding Principal Investigator is responsible for verifying if IBC approval is warranted.
- 31. Radiation Safety Review:** All research involving radiation must meet the requirements of the *“NIH Human Research Protection Program,”* in addition to any grantee radiation safety requirements. The Corresponding Principal Investigator is responsible for verifying if a Radiation Safety Review is warranted.
- 32. Lobbying:** Pursuant to sections 11.062 and 216.347, Florida Statutes, no portion of grant funds will be used for lobbying.
- 33. Insurance:** Grantee must provide adequate liability insurance coverage on a comprehensive basis at all times during the grant period. Upon execution of this grant, unless it is a public college or university as identified in Chapter 1004, Florida Statutes, Grantee accepts full responsibility for identifying and determining the type(s) and extent of liability insurance necessary to provide reasonable financial protections for Grantee and the clients to be served under this grant, if any. Upon execution of this grant, upon request, Grantee must furnish the Department written verification supporting both the determination and existence of such insurance coverage. Such coverage may be provided by a self-insurance program established and operating under the laws of the State of Florida. The Department reserves the right to

require additional insurance where appropriate. Insurance must be secured from a company licensed to do business in the State of Florida.

34. Florida Single Audit Act Financial Audit: Grantee must comply with the provisions of the Florida Single Audit Act, section 215.97, Florida Statutes, as applicable. The following provisions apply:

- a. Grantee is required to maintain separate accounting of revenues and expenditures of funds and maintain sufficient documentation of all expenditures incurred (e.g., invoices, canceled checks, payroll detail, bank statements, etc.) under this grant that evidences that expenditures are:
 - 1) Allowable under the grant and applicable laws, rules, and regulations;
 - 2) Reasonable; and
 - 3) Necessary for Grantee to fulfill the obligations under these Terms and Conditions.
- b. The aforementioned documentation is subject to review by the Department and the State Chief Financial Officer and Grantee will comply timely with any requests for documentation.

35. Termination: This Agreement may be terminated in the following manner:

- a. Termination at Will: This Agreement may be terminated by either party upon no less than one month written notice provided to the other party unless a lesser time is agreed to in writing by the parties.
- b. Termination due to Lack of Funds: In the event funds to finance this grant become unavailable, the Department may terminate this grant upon no less than 24 hours' notice in writing to Grantee. The notice must be delivered by certified mail, return receipt requested, or in person with proof of delivery. The Department will be the final authority as to the availability and adequacy of funds.
- c. Payments: In the event this Agreement is terminated, Grantee will be compensated for any deliverables completed prior to the termination effective date.
- d. Termination for Breach: In the event of research non-compliance or violation of the terms of this Agreement, the Department may terminate this research grant upon no less than 24 hours' notice in writing to Grantee.

36. Indemnification: Unless Grantee is an agency or subdivision of the State of Florida or a public college or university as identified in Chapter 1004, Florida Statutes, Grantee will be liable for and must indemnify, defend, and hold harmless the State of Florida, its officers, employees, and agents to the full extent allowed by law from all losses, expenses, claims, damages, actions, suits, and judgments, consequential or otherwise and including attorneys' fees and costs, arising out of any act, actions, neglect, or omissions by Grantee, its agents, subcontractors, or employees during the performance or operation of this grant, whether direct or indirect, and whether to any person or tangible or intangible property. Only adjudication or judgment after highest appeal is exhausted specifically finding Grantee not liable will excuse performance of this provision.

Nothing in this Agreement is intended to serve as a waiver of sovereign immunity, nor must anything in this grant agreement be construed as consent by a state agency or political subdivision of the State of Florida to be sued by third parties in any matter arising out of this grant agreement. If the Grantee is an agency or subdivision of the State of Florida, the Grantee agrees to be fully responsible for its acts of negligence, or its agents' acts of negligence when acting within the scope of their employment or agency and agrees to be liable for any damages resulting from said negligence. Nothing herein is intended to serve as a waiver of sovereign immunity by any Grantee to whom sovereign immunity may be applicable.

37. Dispute, Dispute Resolution, and Renegotiation:

- a. Failure of this Agreement to cite all applicable state and federal laws and regulations does not waive compliance requirements.
- b. Failure of the Department to declare any default immediately upon the occurrence thereof, or delay in taking any action in connection therewith, does not waive such default. The Department must have the right to declare any default at any time and take such action as might be lawful or authorized hereunder, in law or in equity. No Department waiver of any term, provision, condition, or covenant hereof must be deemed to imply or constitute a further Department waiver of any other term, provision, condition, or covenant hereof, and no payment by the Department must be deemed a waiver of any default hereunder.
- c. Modifications of provisions of this agreement must only be valid when they have been reduced to writing and duly signed by both parties.
- d. Any dispute concerning performance of this Agreement or payment hereunder shall be decided by the Department in writing and submitted to the Grantee for review. The decision is final unless the Grantee submits a written objection to the Department within 10 calendar days from receipt of the decision. Upon receiving an objection, the Department shall provide an opportunity to resolve the dispute by mutual agreement between the parties using a negotiation process to be completed within 7 calendar days from the Department's receipt of the objection. Completion of the negotiation process is a condition precedent to any legal action by the Grantee or the Department concerning this Agreement. Nothing contained in this section is construed to limit the parties' rights of termination pursuant to section 35., above.

38. Contact:

- a. The Department is now using an online grant management system, PeerNet. Sign into PeerNet (<https://peernet.orau.org>) using your existing login and password. All required forms for this grant are in PeerNet. All Principal Investigators will be able to add "contributors," including all post-execution contacts, who can upload documents for the grant they are assigned. All correspondence relating to contractual matters should be directed through PeerNet.
- b. A Vendor Ombudsman has been established within DFS, whose duties include acting as an advocate for Grantees who may be experiencing problems in obtaining timely payment(s) from a state agency. The Vendor Ombudsman may be contacted at (850) 413-5516 or (800) 342-2762, the DFS Consumer Hotline.

39. Background Screening Requirements and Drug Screening Requirements:

- a. Background Screening Requirements:** In the Department's sole and exclusive discretion, it may determine that background screening of some or all of Grantee's officers, agents, employees, subcontractors, or assignees is necessary (collectively individuals). In the event background screenings are required under this agreement, Grantee agrees to the following:
1. Conduct background screenings in accordance with Chapter 435, Florida Statutes, using level 2 screening standards.
 2. Provide the Department with a written attestation confirming that the individual has completed and cleared the level 2 background screening.
 3. Not allow the individual to begin work under this Agreement until that individual has been cleared by the Department.
 4. Be responsible for any costs incurred in meeting this screening requirement, unless otherwise specified by the Department in writing.
- b. Drug Screening Requirements:** Grantee agrees to the following:
1. If the Grantee's officers, agents, employees, subcontractors, or assignees (collectively "individuals") are assigned to work in a Department designated Safety-Sensitive Class and/or Position, under this Agreement, then a drug test must be performed prior to the individual being allowed to start work under this Agreement. If an individual has already been screened by the Provider, then a written attestation confirming that the individual has completed and cleared the drug screening must be submitted to the Department prior to contract execution. If an individual has not been drug screened, notify the Department immediately. No individual can begin work under this Contract until they have been cleared by the Department.
 2. If at any time while performing services under this Contract reasonable suspicion exists to believe that the Provider's staff, which includes, but is not limited to, Provider's officers, agents, employees, subcontractors, or assignees, are under the influence of or impaired by drugs, the Department reserves the right to require the individual to undergo drug testing. The Department may require the individual to cease performing services pending drug test results. In the event of a positive drug test, the Provider must notify the Department in writing and at which time the Department may request a replacement of equal or superior skills and qualifications of the prior individual.
 3. Be responsible for any costs associated with meeting this screening requirement, unless otherwise specified in writing by the Department.

40. Public Entity Crime, Discriminatory Vendor, and Scrutinized Companies:

- a. Public Entity Crime:** Pursuant to section 287.133, Florida Statutes, the following restrictions are placed on the ability of persons convicted of public entity crimes to transact

business with the Department: When a person or affiliate has been placed on the convicted vendor list following a conviction for a public entity crime, he or she may not submit a bid on a contract to provide any goods or services to a public entity, may not submit a bid on a contract with a public entity for the construction or repair of a public building or public work, may not submit bids on leases of real property to a public entity, may not be awarded or perform work as a contractor, supplier, subcontractor, or consultant under a contract with any public entity, and may not transact business with any public entity in excess of the threshold amount provided in section 287.017, Florida Statutes, for CATEGORY TWO for a period of 36 months from the date of being placed on the convicted vendor list.

b. Discriminatory Vendor: Pursuant to section 287.134, Florida Statutes, the following restrictions are placed on the ability of persons convicted of discrimination to transact business with the Department: When a person or affiliate has been placed on the discriminatory vendor list following a conviction for discrimination, he or she may not submit a bid on a contract to provide any goods or services to a public entity, may not submit a bid on a contract with a public entity for the construction or repair of a public building or public work, may not submit bids on leases of real property to a public entity, may not be awarded or perform work as a contractor, supplier, subcontractor, or consultant under a contract with any public entity, and may not transact business with any public entity in excess of the threshold amount provided in section 287.017, Florida Statutes, for CATEGORY TWO for a period of 36 months from the date of being placed on the discriminatory vendor list.

c. Scrutinized Companies: Pursuant to section 287.135, Florida Statutes, if Grantee is found to have been placed on the Scrutinized Companies that Boycott Israel List or is engaged in a boycott of Israel, regardless of the Agreement amount, this Agreement may be terminated at the option of the Department.

41. Annual Compensation Report: Grantee must submit Attachment VII, Annual Compensation Report, including the most recent Internal Revenue Services (IRS) Form 990, detailing the total compensation for the providers' executive leadership teams, to the Department's Grant Manager no later than January 31 of each contract year. Total compensation shall include salary, bonuses, cashed-in leave, cash equivalents, severance pay, retirement benefits, deferred compensation, real-property gifts, and any other payout. If the Provider is exempt from filing IRS Form 990, submit the Attachment VII, without including the IRS Form 990, to the Department. All Annual Compensation Reports must indicate what percent of compensation comes directly from State or Federal funding allocations given to the Provider. In addition, the Provider, by executing this contract, which includes any subsequent amendments, agrees to inform the Department of any changes in total executive compensation specified in the Provider's submitted Annual Compensation Reports.

42. E-Verify Requirement: Effective January 1, 2021, Grantee is required to use the U.S. Department of Homeland Security's E-Verify system to verify the employment eligibility of all newly hired employees used by the Grantee under this Agreement, pursuant to section 448.095, Florida Statutes. Also, the Grantee must include in related subcontracts, if authorized under this Agreement, a requirement that subcontractors performing work or providing services pursuant to this Agreement use the E-Verify system to verify employment eligibility of all newly hired employees used by the subcontractor for the performance of services under this Agreement. The subcontractor must provide the

«Organization»
«PI»
«Grant_Number»

Grantee with an affidavit stating that the subcontractor does not employ, contract with, or subcontract with an unauthorized alien. The Grantee must maintain a copy of such affidavit for the duration of the Agreement. If the Department has a good faith belief that a subcontractor knowingly violated section 448.095(1), Florida Statutes, and notifies the Grantee of such, but the Grantee otherwise complied with this statute, the Grantee must immediately terminate the agreement with the subcontractor.

In Witness Whereof, the parties have caused this ___ page Agreement to be executed by their undersigned, duly authorized officials, and attest to have read the above Agreement and agree to the terms contained within it.

GRANTEE:
«Organization»

«SRO»
«SRO_Title», «SRO_office»


Date

**FLORIDA DEPARTMENT OF
HEALTH:**


Shay Holloway, Acting Director
Division of Community Health Promotion

Date

**Attachment I
 Grant Information**

 <p style="text-align: center;">Florida Biomedical Research Programs Terms and Conditions</p>	
Program:	<i>Ed and Ethel Moore Alzheimer’s Disease Research Program</i>
Program CSFA #:	<i>64.135</i>
Grant Number:	«Grant_Number»
Vendor Identification Number:	«Vendor_Identification_Number»
Grant Category:	«Grant_Category»
Grantee:	«Organization»
Principal Investigator:	«PI»
Grant Title:	«Title»
Grant Abstract:	«Abstract»
Grant Period:	«Grant_Pierod»
Grant Term:	«Grant_TermMonths» <i>months</i>
Total Grant Award:	«Award_Amount»

Attachment II
Schedule of Deliverables and Payments

 Florida Biomedical Research Programs Terms and Conditions			
<i>Ed and Ethel Moore Alzheimer’s Disease Research Program</i> <i>Grant Title: «Title»</i>			
Del. #	Deliverable	Period Covered	Due Dates by COB 5: 00 p.m., E.S.T.
FISCAL YEAR 2022-2023			
1	<ul style="list-style-type: none"> • 3rd Quarter Invoice for «Invoice_Amount» • 3rd Quarter Financial Report • 3rd Quarter Expenditure Report • 3rd Quarter Progress Report • Proof of Liability Insurance 	February 1, 2023 - March 31, 2023	April 28, 2023
2	<ul style="list-style-type: none"> • 4th Quarter Invoice for «Invoice_Amount» • 4th Quarter Financial Report • 4th Quarter Expenditure Report • 4th Quarter Progress Report 	April 1, 2023 – June 30, 2023	July 28, 2023
FISCAL YEAR 2023-2024			
3	<ul style="list-style-type: none"> • 1st Quarter Invoice for «Invoice_Amount» • 1st Quarter Financial Report • 1st Quarter Expenditure Report • 1st Quarter Progress Report • Proof of Liability Insurance • Legislative Report (Reference page 3,5.b.) 	July 1, 2023 – September 30, 2023 Legislative Report Period: February 1, 2023 – September 30, 2023	October 27, 2023
	IF REQUESTING A 6-MONTH NO-COST EXTENSION SUBMIT THE FOLLOWING: <ul style="list-style-type: none"> • No-Cost Extension Request Form • Cumulative Grant Progress Report 	Life of the Grant	October 27, 2023
4	<ul style="list-style-type: none"> • Final Invoice is based on a reconciliation of all costs associated with the project not to exceed «Final_Invoice» • Final Financial Report • Final Expenditure Report • Final Cumulative Grant Progress Report • Final Legislative Report (Reference page 3,5.b.) 	Life of the Grant	March 29, 2024

Mission:

To protect, promote & improve the health of all people in Florida through integrated state, county & community efforts.



Ron DeSantis
Governor

Joseph A. Ladapo, MD, PhD
State Surgeon General

Vision: To be the **Healthiest State** in the Nation

ATTACHMENT VI

Audit Requirements for Awards of State and Federal Financial Assistance

The administration of resources awarded by the Department of Health to recipient organization may be federal or state financial assistance as defined by 2 CFR § 200.40 and/or section 215.97, Florida Statutes, and may be subject to audits and/or monitoring by the Department of Health, as described in this section. For this agreement, the Department of Health has determined the following relationship exist:

_____ Vendor/Contractor (215.97(z), F.S.) and (2 CFR § 200.23). Funds used for goods and services for the Department of Health's own use and creates a procurement relationship with Recipient which is not subject to single audit act compliance requirements for the Federal/State program as a result of this contract agreement.

A vendor/contractor agreement may also be used with an established Service Organization (SO) that is serving as a Third-Party Administrator and in this case, is subject to SSAE18 audit reporting requirements (see Part III. Other Audit Requirements).

_____ Recipient/Subrecipient of state financial assistance (215.97(o)(y), F.S.). Funds may be expended only for allowable costs resulting from obligations incurred during the specified contract period. In addition, any balance of unobligated funds which has been advanced or paid must be refunded to the Department of Health as the state awarding agency. As well as funds paid in excess of the amount to which the recipient/subrecipient is entitled under the terms and conditions of the contract must be refunded to the Department of Health.

_____ Recipient/Subrecipient of federal financial assistance (2 CFR § 200.40). Funds paid in excess of the amount to which the recipient/subrecipient is entitled under the terms and conditions of the contract must be refunded to the Department of Health as the Pass-Through state awarding agency. In addition, the recipient/subrecipient may not earn or keep any profit resulting from Federal financial assistance, unless explicitly authorized by the terms and conditions of the Federal award or this agreement.

Note: A vendor/contractor vs. recipient/subrecipient determination must conclude with the completion of Exhibit 2 to identify the recipient's audit's relationship with the department.

Monitoring

In addition to reviews of audits conducted in accordance with 2 CFR Part 200, Subpart F (formerly A-133) - Audit Requirements, and section 215.97, Florida Statutes (F.S.), as revised (see Audits below), monitoring procedures may include, but not be limited to, on-site visits by Department of Health staff, limited scope audits as defined by 2 CFR §200.425, or other procedures. By entering into this agreement, the recipient agrees to comply and cooperate with any monitoring procedures or processes deemed appropriate by the Department of Health. In the event the Department of Health determines that a limited scope audit of the recipient is appropriate, the recipient agrees to comply with any additional instructions provided by Department of Health staff to the recipient regarding such audit. The recipient further agrees to comply and cooperate with any inspections, reviews, investigations, or audits deemed necessary by the Chief Financial Officer (CFO) or Auditor General.

AUDIT GUIDANCE

PART I: FEDERALLY FUNDED

This part is applicable if Recipient is a State or local government or a non-profit organization as defined in 2 CFR §200.90, §200.64, and §200.70.

1. If a recipient expends \$750,000 or more in Federal awards during its fiscal year, the recipient must have a single or program-specific audit conducted in accordance with the provisions of 2 CFR 200, Subpart F - Audit Requirements. **EXHIBIT 1** to this form lists the federal resources awarded through the Department of Health by this agreement. In determining the federal awards expended in its fiscal year, the recipient shall consider all sources of federal awards, including federal resources received from the Department of Health. The determination of amounts of federal awards expended should be in accordance with the guidelines established in 2 CFR §§200.502-503. An audit of the recipient conducted by the Auditor General in accordance with the provisions of 2 CFR §200.514 will meet the requirements of this Part.
2. In connection with the audit requirements addressed in Part I, paragraph 1, Recipient shall fulfill the requirements relative to auditee responsibilities as provided in 2 CFR §§ 200.508-.512.
3. If a recipient expends less than \$750,000 in Federal awards in its fiscal year, the recipient is not required to have an audit conducted in accordance with the provisions of 2 CFR 200, Subpart F - Audit Requirements. If the recipient expends less than \$750,000 in federal awards in its fiscal year and elects to have an audit conducted in accordance with the provisions of 2 CFR 200, Subpart F - Audit Requirements, the cost of the audit must be paid from non-federal resources (i.e., the cost of such an audit must be paid from recipient resources obtained from other than federal entities).

Note: Audits conducted in accordance with this part shall cover the entire organization for the organization's fiscal year. Compliance findings related to contracts with the Florida Department of Health (FDOH) shall be based on the contract agreement's requirements, including any rules, regulations, or statutes referenced in the contract. The financial statements shall disclose whether the matching requirement was met for each applicable contract. All questioned costs and liabilities due to the FDOH shall be fully disclosed in the audit report with reference to the Department of Health contract involved. If not otherwise disclosed as required by 2 CFR § 200.510, the schedule of expenditures of Federal awards shall identify expenditures by funding source and contract number for each contract with the FDOH in effect during the audit period.

Financial reporting packages required under this part must be submitted within the earlier of 30 days after receipt of the audit report or 9 months after the end of Recipient's fiscal year end.

PART II: STATE FUNDED

This part is applicable if the recipient is a nonstate entity as defined by section 215.97(1)(n), Florida Statutes.

1. If a recipient expends a total amount of state financial assistance equal to or in excess of \$750,000 in any fiscal year of such recipient (for fiscal years ending June 30, 2017 or thereafter), recipient must have a State single or project-specific audit for such fiscal year in accordance with section 215.97, Florida Statutes; applicable rules of the Department of Financial Services; Chapter 10.550 (local governmental entities) or Chapter 10.650 (nonprofit and for-profit organizations), Rules of the Auditor General. **EXHIBIT I** to this contract indicates state financial assistance awarded through the Department of Health by this contract. In determining the state financial assistance expended in its fiscal year, recipient shall consider all sources of state financial assistance, including state financial assistance received from the Department of Health, other state agencies, and other nonstate entities. State financial assistance does not include Federal direct or pass-through awards and resources received by a nonstate entity for Federal program matching requirements.
2. In connection with the audit requirements addressed in Part II, paragraph 1, recipient shall ensure that the audit complies with the requirements of section 215.97(8), Florida Statutes. This includes submission of a financial reporting package as defined by section 215.97(2), Florida Statutes, and Chapter 10.550 (local governmental entities) or Chapter 10.650 (nonprofit and for-profit organizations), Rules of the Auditor General.
3. If a recipient expends less than \$750,000 in state financial assistance in its fiscal year (for fiscal years ending June 30, 2017 or thereafter), an audit conducted in accordance with the provisions of section 215.97, Florida Statutes, is not required. In the event that a recipient expends less than \$750,000 in state financial assistance in its fiscal year and elects to have an audit conducted in accordance with the provisions of section 215.97, Florida Statutes, the cost of the audit must be paid from the nonstate entity's resources (i.e., the cost of such an audit must be paid from recipient resources obtained from other than state funds).

Note: An audit conducted in accordance with this part shall cover the entire organization for the organization's fiscal year. Compliance findings related to contracts with the FDOH shall be based on the contract's requirements, including any applicable rules, regulations, or statutes. The financial statements shall disclose whether the matching requirement was met for each applicable contract. All questioned costs and liabilities due to the FDOH shall be fully disclosed in the audit report with reference to the FDOH contract involved. If not otherwise disclosed as required by Florida Administrative Code Rule 69I-5.003, the schedule of expenditures of state financial assistance shall identify expenditures by contract number for each contract with the FDOH in effect during the audit period.

Financial reporting packages required under this part must be submitted within 45 days after delivery of the audit report, but no later than 9 months after recipient's fiscal year end for local governmental entities. Non-profit or for-profit organizations are required to be submitted **within 45 days after delivery of the audit report, but no later than 9 months after recipient's fiscal year end**. Notwithstanding the applicability of this portion, the FDOH retains all right and obligation to monitor and oversee the performance of this contract as outlined throughout this document and pursuant to law.

PART III: OTHER AUDIT REQUIREMENTS

This part is applicable to a contractor, vendor and/or provider organization serving as a third-party administrator on behalf of FDOH programs and is classified or determined in the FDOH contract agreement to be a Service Organization (SO).

If the contracted entity is determined to be a Service Organization (SO), the entity must perform an attestation to the Service Organization Controls (SOC) and submit to FDOH a “Statement on Standards for Attestation Engagements (SSAE18) audit report within the assigned timeframe as agreed upon in the SO’s contract agreement. The hired Auditor must make an evaluation consistent with the FDOH contract terms and conditions to determine which SSAE18 report types to perform for the required SOC types. Below are the options available for the SSAE18 reports.

TYPES:

1. **SOC 1** – A report on controls over financial reporting.
 - **Type 1 Report** - Report on the fairness of the presentation of management’s description of the service organization’s system and the suitability of the design of the controls to achieve the related control objectives included in the description as of a specified date.
 - **Type 2 Report** - Report on the fairness of the presentation of management’s description of the service organization’s system and the suitability of the design and **operating effectiveness** of the controls to achieve the related control objectives included in the description throughout a specified period. (**Auditor conducts testing**)
2. **SOC 2** – A report on controls that may be relevant to security, availability, processing Integrity, confidentiality or privacy. These reports are intended to meet the needs of a broad range of users that need detailed information and assurance about the controls at a service organization relevant to security, availability, and processing integrity of the systems the service organization uses to process users’ data and the confidentiality and privacy of the information processed by these systems. These reports can play an important role in:
 - Oversight of the organization.
 - Vendor management programs.
 - Internal corporate governance and risk management processes.
 - Regulatory oversight.
 - **Type 1 Report** - Report on the fairness of the presentation of management’s description of the service organization’s system and the suitability of the design of the controls to achieve the related control objectives included in the description as of a specified date.
 - **Type 2 Report** - Report on the fairness of the presentation of management’s description of the service organization’s system and the suitability of the design and **operating effectiveness** of the controls to achieve the related control objectives included in the description throughout a specified period. (**Auditor conducts testing**)

PART IV: REPORT SUBMISSION

1. Copies of single audit reporting packages for code of state financial assistance (CSFA) and code of federal domestic assistance (CFDA) conducted in accordance with **2 CFR § 200.512 and section 215.97(2), Florida Statutes**, shall be submitted by or on behalf of recipient directly to:

- A. The Department of Health as follows:

SingleAudits@flhealth.gov

Pursuant to 2 CFR § 200.521, and section 215.97(2), Florida Statutes, recipient shall submit an electronic copy of the reporting package and any management letter issued by the auditor to the Department of Health.

Audits must be submitted in accordance with the instructions set forth in Exhibit 3 hereto and accompanied by the “Single Audit Data Collection Form, Exhibit 4.” Files which exceed electronic email capacity may be submitted on a CD or other electronic storage medium and mailed to:

Florida Department of Health
Bureau of Finance and Accounting
Attention: FCAM, Single Audit Review
4052 Bald Cypress Way, Bin B01
Tallahassee, FL 32399-1701.

- B. The Auditor General’s Office as follows:

One electronic copy email by or on behalf of recipient directly to the Auditor General’s Office at: flaudgen_localgovt@aud.state.fl.us.

One paper copy mail to:

Auditor General’s Office
Claude Pepper Building, Room 401
111 West Madison Street
Tallahassee, Florida 32399-1450

2. In addition to item 1, electronic copies of reporting packages for federal financial assistance (CFDA) conducted in accordance with **2 CFR § 200.512** shall also be submitted by or on behalf of recipient directly to each of the following:

- A. The Federal Audit Clearinghouse (FAC), the Internet Data Entry System (IDES) is the place to submit the Federal single audit reporting package, including form SF-SAC, for Federal programs. Single audit submission is required under the Single Audit Act of 1984 (amended in 1996) and 2 CFR § 200.36 and § 200.512. The Federal Audit Clearinghouse requires electronic submissions as the only accepted method for report compliances. FAC’s website address is: <https://harvester.census.gov/facweb/>
- B. When applicable, other Federal agencies and pass-through entities in accordance with 2 CFR §200.331 and § 200.517.

«Organization»

«PI»

«Grant_Number»

- C. Copies of SSAE18 reports and supporting documents shall be submitted by or on behalf of SO/Third Party Administrator **directly to the FDOH designated Contract Manager (CM)** as outlined in each SO contract agreement.

Note: Any reports, management letter, or other information required to be submitted to the FDOH pursuant to this contract shall be submitted timely in accordance with 2 CFR § 200.512 and Florida Statutes, Chapter 10.550 (local governmental entities) or Chapter 10.650 (nonprofit and for-profit organizations), Rules of the Auditor General, as applicable.

Recipients, when submitting financial reporting packages to the FDOH for audits done in accordance with 2 CFR § 500.512 or Chapter 10.550 (local governmental entities) or Chapter 10.650 (nonprofit and for-profit organizations), Rules of the Auditor General, should indicate the date that the reporting package was delivered to recipient in correspondence accompanying the reporting package.

PART V: RECORD RETENTION

Recipient shall retain sufficient records demonstrating its compliance with the terms of this contract for a period of six years from the date the audit report is issued and shall allow the Department of Health or its designee, the CFO, or the Auditor General access to such records upon request. Recipient shall ensure that audit working papers are made available to the Department of Health, or its designee, CFO, or Auditor General upon request for a period of six years from the date the audit report is issued, unless extended in writing by the FDOH.

End of Text

EXHIBIT 1

Contract #: «Grant_Number»

Federal Award Identification #: _____

1. FEDERAL RESOURCES AWARDED TO THE SUBRECIPIENT PURSUANT TO THIS AGREEMENT CONSIST OF THE FOLLOWING:

Federal Agency 1 _____ CFDA# _____ Title _____ \$ _____

Federal Agency 2 _____ CFDA# _____ Title _____ \$ _____

TOTAL FEDERAL AWARDS \$ _____

COMPLIANCE REQUIREMENTS APPLICABLE TO THE FEDERAL RESOURCES AWARDED PURSUANT TO THIS AGREEMENT ARE AS FOLLOWS:

2. STATE RESOURCES AWARDED TO THE RECIPIENT PURSUANT TO THIS AGREEMENT CONSIST OF THE FOLLOWING:

State financial assistance subject to section 215.97, Florida Statutes: CSFA# <<CSFA>> _____

Title: Ed and Ethel Moore Alzheimer's Disease Research Program

«Award_Amount»

TOTAL STATE FINANCIAL ASSISTANCE AWARDED PURSUANT TO SECTION 215.97, FLORIDA STATUTES
«Award_Amount»

COMPLIANCE REQUIREMENTS APPLICABLE TO STATE RESOURCES AWARDED PURSUANT TO THIS AGREEMENT ARE AS FOLLOWS:

All direct costs must be specifically and directly related to the project, necessary for the project's completion, adequately justified, and made during the active grant period. Any other costs are disallowed. Additionally, the following items shall NOT be paid for with grant funds: Florida Department of Health personnel salary, construction, renovation, or remodeling, international travel (including Canada), vehicles, entertainment, employment subsidies, dues/membership fees, lobbying, meals/food (other than as part of travel costs), malpractice insurance premiums.

Financial assistance not subject (exempt) to section 215.97, Florida Statutes or 2 CFR § 200.40: \$ _____

Financial assistance not subject (exempt) to section 215.97, Florida Statutes or 2 CFR § 200.40: \$ _____

Matching and Maintenance of Effort *

Matching resources for federal Agency(s):

Agency: _____ CFDA# _____ Title _____ \$ _____

Maintenance of Effort (MOE):

Agency: _____ CFDA# _____ Title _____ \$ _____

*Matching Resources, MOE, and Financial Assistance not subject to section 215.97, Florida Statutes or 2 CFR § 200.306 amounts should not be included by recipient when computing the threshold for single audit requirements totals. However, these amounts could be included under notes in the financial audit or footnoted in the Schedule of Expenditures of Federal Awards and State Financial Assistance (SEFA). Matching, MOE, and Financial Assistance not subject to section. 215.97, Florida Statutes or 2 CFR § 200.306 is not considered State or Federal Assistance.

EXHIBIT 2

PART I: AUDIT RELATIONSHIP DETERMINATION

Recipients who receive state or federal resources may or may not be subject to the audit requirements of 2 CFR § 200.500, and/or section 215.97, Florida Statutes, recipients who are determined to be recipients or subrecipients of federal awards and/or state financial assistance may be subject to the audit requirements if the audit threshold requirements set forth in Part I and/or Part II of Exhibit 1 is met. Recipients who have been determined to be vendors are not subject to the audit requirements of 2 CFR § 200.501, and/or section 215.97, Florida Statutes. Recipients who are “higher education entities” as defined in Section 215.97(2)(h), Florida Statutes, and are recipients or subrecipients of state financial assistance, are also exempt from the audit requirements of Section 215.97(2)(a), Florida Statutes. Regardless of whether the audit requirements are met, recipients who have been determined to be recipients or subrecipients of Federal awards and/or state financial assistance must comply with applicable programmatic and fiscal compliance requirements.

For the purpose of single audit compliance requirements, the Recipient has been determined to be:

____ Vendor/Contractor not subject to 2 CFR § 200.501 and/or section 215.97, Florida Statutes
«Private» Recipient/subrecipient subject to 2 CFR § 200.501 and/or section 215.97, Florida Statutes
____ Exempt organization not subject to 2 CFR § 200.501; For Federal awards for-profit subrecipient organizations are exempt as specified in 2 CFR § 200.501(h).
«Public» Exempt organization not subject to section 215.97, Florida Statutes, for state financial assistance projects, public universities, community colleges, district school boards, branches of state (Florida) government, and charter schools are exempt. Exempt organizations must comply with all compliance requirements set forth within the contract.

For other audit requirements, the Recipient has been determined to be:

____ Service Organization (SO) subject to SSAE18 reporting requirements

NOTE: If a recipient is determined to be a recipient/subrecipient of federal and or state financial assistance and has been approved by the department to subcontract, it must comply with section 215.97(7), Florida Statutes, and Florida Administrative Code Rule 69I-.5006, [state financial assistance] and 2 CFR § 200.330 [federal awards].

PART II: FISCAL COMPLIANCE REQUIREMENTS

FEDERAL AWARDS OR STATE MATCHING FUNDS ON FEDERAL AWARDS. Recipients who receive Federal awards, state maintenance of effort funds, or state matching funds on Federal awards and who are determined to be a subrecipient must comply with the following fiscal laws, rules and regulations:

1. 2 CFR Part 200- Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards.
2. Reference Guide for State Expenditures.
3. Other fiscal requirements set forth in program laws, rules, and regulations.

*Some Federal programs may be exempted from compliance with the Cost Principles Circulars as noted in the 2 CFR § 200.401(5) (c).

**For funding passed through U.S. Health and Human Services, 45 CFR Part 92; for funding passed through U.S. Department of Education, 34 CFR Part 80.

STATE FINANCIAL ASSISTANCE. Recipients who receive state financial assistance and who are determined to be a recipient/subrecipient must comply with the following fiscal laws, rules and regulations:

1. Section 215.97, Florida Statutes
2. Florida Administrative Code Chapter 69I-5,
3. State Projects Compliance Supplement
4. Reference Guide for State Expenditures
5. Other fiscal requirements set forth in program laws, rules and regulations

This document may be obtained [online through the FLHealth website under Audit Guidance](#). *Enumeration of laws, rules and regulations herein is not exhaustive or exclusive. Funding to recipients will be held to applicable legal requirements whether or not outlined herein.

End of Text

EXHIBIT 3

INSTRUCTIONS FOR ELECTRONIC SUBMISSION OF SINGLE AUDIT REPORTS

Part I: Submission to FDOH

Single Audit reporting packages (“SARP”) must be submitted to the Department in an electronic format. This change will eliminate the need to submit multiple copies of the reporting package to the Contract Managers and various sections within the Department and will result in efficiencies and cost savings to recipient and the Department. Upon receipt, the SARP’s will be posted to a secure server and accessible to Department staff.

The electronic copy of the SARP should:

- Be in a Portable Document Format (PDF).
- Include the appropriate letterhead and signatures in the reports and management letters.

Be a single document. However, if the financial audit is issued separately from the Single Audit reports, the financial audit reporting package may be submitted as a single document and the Single Audit reports may be submitted as a single document. Documents which exceed 8 megabytes (MB) may be stored on a CD and mailed to: Bureau of Finance & Accounting, Attention: FCAM, Single Audit Review, 4052 Bald Cypress Way, Bin B01 (HAFA), Tallahassee, FL 32399-1701.

- Be an exact copy of the final, signed SARP provided by the Independent Audit firm.
- Not have security settings applied to the electronic file.
- Be named using the following convention: [fiscal year] [name of the audited entity exactly as stated within the audit report].pdf. For example, if the SARP is for the 2016-17 fiscal year for the City of Gainesville, the document should be entitled 2016 City of Gainesville.pdf.
- Be accompanied by the attached “Single Audit Data Collection Form.” This document is necessary to ensure that communications related to SARP issues are directed to the appropriate individual(s) and that compliance with Single Audit requirements is properly captured.

Questions regarding electronic submissions may be submitted via e-mail to SingleAudits@flhealth.gov or by telephone to the Single Audit Review Section at (850) 245-4185.

Part II: Submission to Federal Audit Clearinghouse

Click [Here](#) for instructions and guidance to submit the completed SF-SAC report to the Federal Audit Clearinghouse website or click [Here](#) to access the SF-SAC Worksheet & Single Audit Component Checklist Form.

Part III: Submission to Florida Auditor General

Click [Here](#) for questions and other instructions for submitting Single SAC reports to the State of Florida, Auditor General’s Office

EXHIBIT 4

Single Audit Data Collection Form

Part 1: GENERAL INFORMATION

<p>1. Fiscal period ending date for the Single Audit.</p> <div style="border: 1px solid black; padding: 5px; margin: 10px auto; width: 150px;"> <table style="width: 100%; border-collapse: collapse;"> <tr> <td style="text-align: center; width: 33%;">Month</td> <td style="text-align: center; width: 33%;">Day</td> <td style="text-align: center; width: 33%;">Year</td> </tr> <tr> <td style="text-align: center;">/</td> <td style="text-align: center;">/</td> <td></td> </tr> </table> </div>	Month	Day	Year	/	/		<p>2. Auditee Identification Number</p> <p>a. Primary Employer Identification Number (EIN)</p> <div style="margin: 10px 0;"> <table style="border-collapse: collapse;"> <tr> <td style="border: 1px solid black; width: 20px; height: 20px;"></td> <td style="border: 1px solid black; width: 20px; height: 20px;"></td> <td style="width: 10px; text-align: center;">--</td> <td style="border: 1px solid black; width: 20px; height: 20px;"></td> <td style="border: 1px solid black; width: 20px; height: 20px;"></td> <td style="border: 1px solid black; width: 20px; height: 20px;"></td> <td style="border: 1px solid black; width: 20px; height: 20px;"></td> <td style="border: 1px solid black; width: 20px; height: 20px;"></td> <td style="border: 1px solid black; width: 20px; height: 20px;"></td> <td style="border: 1px solid black; width: 20px; height: 20px;"></td> </tr> </table> </div> <p>b. Are multiple EINs covered in this report <input type="checkbox"/> Yes <input type="checkbox"/> No</p> <p>c. If "yes", complete No. 3.</p>			--							
Month	Day	Year															
/	/																
		--															

<p>3. ADDITIONAL ENTITIES COVERED IN THIS REPORT</p> <p style="text-align: center;">Employer Identification #</p> <table style="width: 100%; border-collapse: collapse; margin-top: 10px;"> <tr> <td style="border: 1px solid black; width: 20px; height: 20px;"></td> <td style="border: 1px solid black; width: 20px; height: 20px;"></td> <td style="width: 10px; text-align: center;">--</td> <td style="border: 1px solid black; width: 20px; height: 20px;"></td> <td style="border: 1px solid black; width: 20px; height: 20px;"></td> <td style="border: 1px solid black; width: 20px; height: 20px;"></td> <td style="border: 1px solid black; width: 20px; height: 20px;"></td> <td style="border: 1px solid black; width: 20px; height: 20px;"></td> <td style="border: 1px solid black; width: 20px; height: 20px;"></td> <td style="border: 1px solid black; width: 20px; height: 20px;"></td> <td style="border: 1px solid black; width: 20px; height: 20px;"></td> <td style="border: 1px solid black; width: 20px; height: 20px;"></td> </tr> <tr> <td style="border: 1px solid black; width: 20px; height: 20px;"></td> <td style="border: 1px solid black; width: 20px; height: 20px;"></td> <td style="width: 10px; text-align: center;">--</td> <td style="border: 1px solid black; width: 20px; height: 20px;"></td> <td style="border: 1px solid black; width: 20px; height: 20px;"></td> <td style="border: 1px solid black; width: 20px; height: 20px;"></td> <td style="border: 1px solid black; width: 20px; height: 20px;"></td> <td style="border: 1px solid black; width: 20px; height: 20px;"></td> <td style="border: 1px solid black; width: 20px; height: 20px;"></td> <td style="border: 1px solid black; width: 20px; height: 20px;"></td> <td style="border: 1px solid black; width: 20px; height: 20px;"></td> <td style="border: 1px solid black; width: 20px; height: 20px;"></td> </tr> <tr> <td style="border: 1px solid black; width: 20px; height: 20px;"></td> <td style="border: 1px solid black; width: 20px; height: 20px;"></td> <td style="width: 10px; text-align: center;">--</td> <td style="border: 1px solid black; width: 20px; height: 20px;"></td> <td style="border: 1px solid black; width: 20px; height: 20px;"></td> <td style="border: 1px solid black; width: 20px; height: 20px;"></td> <td style="border: 1px solid black; width: 20px; height: 20px;"></td> <td style="border: 1px solid black; width: 20px; height: 20px;"></td> <td style="border: 1px solid black; width: 20px; height: 20px;"></td> <td style="border: 1px solid black; width: 20px; height: 20px;"></td> <td style="border: 1px solid black; width: 20px; height: 20px;"></td> <td style="border: 1px solid black; width: 20px; height: 20px;"></td> </tr> <tr> <td style="border: 1px solid black; width: 20px; height: 20px;"></td> <td style="border: 1px solid black; width: 20px; height: 20px;"></td> <td style="width: 10px; text-align: center;">--</td> <td style="border: 1px solid black; width: 20px; height: 20px;"></td> <td style="border: 1px solid black; width: 20px; height: 20px;"></td> <td style="border: 1px solid black; width: 20px; height: 20px;"></td> <td style="border: 1px solid black; width: 20px; height: 20px;"></td> <td style="border: 1px solid black; width: 20px; height: 20px;"></td> <td style="border: 1px solid black; width: 20px; height: 20px;"></td> <td style="border: 1px solid black; width: 20px; height: 20px;"></td> <td style="border: 1px solid black; width: 20px; height: 20px;"></td> <td style="border: 1px solid black; width: 20px; height: 20px;"></td> </tr> </table>			--												--												--												--										<p style="text-align: center;">Name of Entity</p> <hr style="border: 0; border-top: 1px solid black; margin-bottom: 5px;"/> <hr style="border: 0; border-top: 1px solid black; margin-bottom: 5px;"/> <hr style="border: 0; border-top: 1px solid black; margin-bottom: 5px;"/> <hr style="border: 0; border-top: 1px solid black; margin-bottom: 5px;"/>
		--																																															
		--																																															
		--																																															
		--																																															

4. AUDITEE INFORMATION

a. Auditee name: _____

Auditee Primary DUNS#: _____

b. Auditee address (number and street)

City _____

State _____ Zip Code _____

c. Auditee contact

Name: _____

Title: _____

d. Auditee contact telephone

() - _____

e. Auditee contact FAX

() - _____

f. Auditee contact E-mail

5. PRIMARY AUDITOR INFORMATION

a. Primary auditor name: _____

b. Primary auditor address (number and street)

City _____

State _____ Zip Code _____

c. Primary auditor contact

Name: _____

Title: _____

d. Primary auditor contact telephone

() - _____

e. Primary auditor E-mail

() - _____

f. Audit Firm License Number

	<p>AUDITEE CERTIFICATION Date ____/____/____</p> <p>Date Audit Received from Auditor: ____/____/____</p> <p>Name of Certifying Official: _____ <i>(Please print clearly)</i></p> <p>Title of Certifying Official: _____ <i>(Please print clearly)</i></p> <p>Signature of Certifying Official: _____</p>
--	--

ANNUAL COMPENSATION REPORTING FORM



Guidance

Most tax-exempt organizations are required to file an [annual return](#) with the Internal Revenue Service (IRS). Whether your organization meet this IRS filing requirement or is exempt from the [IRS 990](#) filing, the Florida Department of Health (Department) requires that this form be completed and submitted annually to support your organization’s status with the executive compensation requirements.

Business Legal Name	Street Address Including City, State, and ZIP Code
Telephone	Department Contract #
Email	UEI or DUNS #
FEIN /Tax Id	Parent FEIN/Tax Id (if different)

Check here if 50% or more of your organization’s revenues come from Federal, State or Other grant funds.

IRS Filing Status

Organization Types

Reported Status

Not Exempt

Exempt From 990
(Must complete all sections below)

Top 5 Highest Paid Officers (Name/Title)

Total Amount Paid in Compensation and Benefits

	<u>Top 5 Highest Paid Officers (Name/Title)</u>	<u>Total Amount Paid in Compensation and Benefits</u>
1. Name /Title		
2. Name /Title		
3. Name /Title		
4. Name /Title		
5. Name /Title		

I attest that no salary and/or compensation benefits were allocated to Department program funds in excess of the Federal Executive Pay Scale threshold for Level II - \$197,300 ([Click Here to access the Pay Table](#)).

Signature: _____

Date of Signature: _____

ATTACHMENT VII

INSTRUCTIONS FOR COMPLETING THE FDOH EXECUTIVE COMPENSATION REPORTING FORM

Most tax -exempt organizations are required to file an [annual return](#). Which form an organization must file with the Internal Revenue Service (IRS) [generally](#) depends on the organization’s financial activities. This FDOH form must be completed by all organizations (non profits and pro - profits) who are awarded with state appropriation funds (federal/state) as a recipient of state financial assistance or as a sub-recipient of federal financial assistance. Please use the instructions below as a guide for completing each section of the FDOH form.

Business Legal Name	Street Address Including City, State, and ZIP Code
Telephone	FDOH Contract #
Email	UEI/DUNS #
FEIN/Tax Id	Parent FEIN/Tax Id (if different)
Business legal Name	Insert the exact name as shown on the IRS Tax Id registration certificate, Florida Sun Biz, MFMP registration or the organization name on the FDOH contract agreement. If the contract legal name is different from the registered legal name, please coordinate, and contact your FDOH’s assigned Contract Manager.
Street Address	Input the mailing or physical address including zip code your organization uses for formal communication. This address may be different from the operating address/es where clients receive Services.
Telephone	Provide a direct ten (10) digits phone contact including extension number when applicable for follow up questions and inquiries.
FDOH Contract #	Insert all contract numbers for which your organization either received from FDOH as assets (equipment) and/or cash receipts during the reporting fiscal year.
Email	Please provide a secure email address for official business communications with FDOH.
UEI/DUNS #	Obtaining a DUNS number is a requirement for all grantees of federal funds. If your organization is funded with any federal funds (e.g., your contract agreement is labeled with an Assistance Listing Number (ALN, formerly CFDA), please input your DUNS or your assigned Unique Entity Identifier (UEI) number in this box..
FEIN/Tax Id	Please insert your exact nine (9) digits registered Tax Identification number. This should be the same as the Tax Id number on the FDOH contractual agreement. If different, please coordinate with your FDOH assigned Contract Manager.

APPENDIX II: SUPPORTING DOCUMENTS

OMB No. 0925-0001 and 0925-0002 (Rev. 10/2021 Approved Through 09/30/2024)

1. BIOGRAPHICAL SKETCH

Provide the following information for the Senior/key personnel and other significant contributors. Follow this format for each person. **DO NOT EXCEED FIVE PAGES.**

NAME:

eRA COMMONS USERNAME (credential, e.g., agency login):

POSITION TITLE:

EDUCATION/TRAINING (*Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and residency training if applicable. Add/delete rows as necessary.*)

INSTITUTION AND LOCATION	DEGREE (if applicable)	Completion Date MM/YYYY	FIELD OF STUDY

- **Personal Statement**

- **Positions, Scientific Appointments, and Honors**

- **Contributions to Science**

Please refer to the Biographical Sketch instructions on the [Biosketch Format Pages, Instructions and Samples](#), in order to complete sections A, B, C, and D of the Biographical Sketch.

2. HUMAN SUBJECTS FORM

If human subjects are involved in this project at any point at any site, answer the following questions.

Although no specific word limit applies to this section of the application, please be concise.

Human Participant Protection/Institutional Review Board Approval

- IRB approval has been obtained
- IRB approval is pending

Describe the proposed involvement of human subjects in the work outlined in the Research/Project Plan section in the space provided below.

Describe the characteristics of the subject population, including their anticipated number, age range, gender, race, ethnicity, and health status. Identify the criteria for inclusion or exclusion of any subpopulation in the space provided below.

Explain the rationale for the involvement of special classes of subjects, such as pregnant women, children, prisoners, institutionalized individuals, or others who are likely to be vulnerable in the space provided below.

Identify the sources of research/project material obtained from individually identifiable living human subjects in the form of specimens, records, or data. Indicate whether the material or data will be obtained specifically for project purposes or whether use will be made of existing specimens, records, or data. Indicate whether data about specimens will be submitted to, or held for inspection by, the Food and Drug Administration (FDA) as part of an application for marketing a drug or device in the space provided below.

Describe plans for the recruitment of subjects and the consent procedures to be followed. Include how consent will be sought and obtained, who will seek it, the nature of the information to be provided to prospective subjects, and the method of documenting consent. State if the IRB has authorized a modification or waiver of the elements of consent or the requirement for documentation of consent. The informed consent form, which must have IRB approval, should be submitted to the Biomedical Research Program only if requested.

Describe potential risks to the subjects (physical, psychological, social, legal, or other) and assess their likelihood and seriousness in the space provided below.

Where appropriate, describe alternative treatments and procedures that might be advantageous to the subjects in the space provided below.

Describe the procedures for protecting against or minimizing potential risks, including risks to confidentiality, and assess their likely effectiveness in the space provided below.

Where appropriate, discuss provisions for ensuring necessary medical or professional intervention in the event of adverse effects to the subjects. Also, where appropriate, describe the provisions for monitoring the data collected to ensure the safety and privacy of subjects in the space provided below.

Discuss why the risks to subjects are reasonable in relation to the anticipated benefits to subjects and in relation to the importance of the knowledge that may reasonably be expected to result. If a test article (investigational new drug, device, or biologic) is involved, name the test article and state whether the 30-day interval between submission of applicant certification to the Food and Drug Administration and its response has elapsed or has been waived and/or whether use of the test article has been withheld or restricted by the FDA.

3. GENDER AND MINORITY INCLUSION FOR RESEARCH INVOLVING HUMAN SUBJECTS

Women and members of minority groups and their subpopulations should be included in all research funded by the Department, unless there is a reason that that inclusion is inappropriate with respect to the health of the subjects or the purpose of the research.

Exclusion under other circumstances may be made based on a compelling rationale and justification. Cost is not an acceptable reason for exclusion, except when the study would duplicate data from other sources. Women of childbearing potential should not be routinely excluded from participation in clinical research. This applies to research subjects of all ages. Address the inclusion of women and members of minority groups and their subpopulations in developing a research design appropriate to the scientific objectives of the study. Describe the composition of the proposed study population in terms of gender and racial/ethnic group and provide a rationale for selection of such subjects in the space provided below.

Provide the proposed enrollment beginning and end dates. Include a description of proposed outreach programs for recruiting women and minorities as participants in the space provided below.

Provide compelling rationale and justification for requesting any exclusion noted above. When proposing Phase III clinical trials, show whether clinically important gender or race/ethnicity differences are to be expected, and how the trial is designed to accommodate any differences.

4. RECOMBINANT DNA MOLECULES FORM

Describe use of recombinant DNA molecules in the research.

Describe the rationale and procedures for use of recombinant DNA molecules in the research.

5. STEM CELL RESEARCH FORM

If the proposed project involves stem cells at any time during the project, answer the questions below.

Type of Stem Cell

If activities involving stem cells, whether exempt from Federal regulations for the protection of human subjects, are planned at any time during the proposed project period, either at the applicant organization or at any other site or collaborating organization, check the type of stem cell.

If the project involves stem cells, please identify the source(s) of stem cells being used and include a very brief description of the relevant research activity. If the cell line(s) proposed to be

used are not

from the NIH Stem Cell Registry (Registry), provide a strong justification for why an appropriate cell line cannot be chosen from the Registry at this time.

Provide a detailed description of the proposed use of animals in the work outlined in the Research/Project Plan section or Vertebrate Animals form. Identify the species, strains, ages, sex, and numbers of animals to be used in the proposed work. **Vertebrate Animals Form**

If the proposed project involves vertebrate animals at any time during the project, answer the questions below.

Although no specific word limit applies to this section of the application, please be concise.

Provide a detailed description of the proposed use of animals in the work outlined in the Research/Project Plan section. Identify the species, strains, ages, sex, and numbers of animals to be used in the proposed work. Provide a description if the animals will be used at a collaborating site, or location other than the principal researcher's organization.

Justify the use of animals, the choice of species, and the numbers to be used. If animals are in short supply, costly, or to be used in large numbers, provide an additional rationale for their selection and numbers.

Provide information on the maintenance and veterinary care of the animals involved.

Describe the procedures for ensuring that discomfort, distress, pain, and injury will be limited to that which is unavoidable in the conduct of scientifically sound research.

Describe the use of analgesic, anesthetic, and tranquilizing drugs and/or comfortable restraining devices, where appropriate, to minimize discomfort, distress, pain, and injury.

Describe any method of euthanasia to be used and the reasons for its selection. State whether this method is consistent with the recommendations of the Panel on Euthanasia of the American Veterinary Medical Association. If not, present a justification for not following the recommendations.

Institutional Animal Care and Use Committee Approval

- IACUC approval has been granted within the previous three years.
- IACUC approval is pending.